

# **Annual Report of the Academic Output of DCRI Clinical Research Fellows**

Academic Year: July 2018–June 2019

**Training**

Physical Therapy School (2004–2006): University of Florida, Gainesville, FL

Sports Physical Therapy Residency (2006–2007): UFHealth, University of Florida, Gainesville, FL

PhD/MPH Training (2013–2017): University of Florida, Gainesville, FL

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

**Awards/Grants**

Focus on Therapeutic Outcomes (FOTO) D.L. Hart Memorial Outcomes Research Grant (2018–2020): Refining Psychological Domain Measurement Using Item Response Theory Analysis

Duke Clinical Research Institute Executive Director’s Pathway for Supplemental Funding (2018–2019): Comorbidity Subgroups among Medicare Beneficiaries Seeking Healthcare for Knee Osteoarthritis

STOP Sports Injuries Award, American Orthopaedic Society for Sports Medicine (AOSSM)

Chattanooga Research Award, American Physical Therapy Association (APTA)

## ANGELA LOWENSTERN, MD – CO-CHIEF FELLOW

### Training

Medical School (2008–20012): University of Michigan, Ann Arbor, MI

Internal Medicine Residency (2012–2015): Duke University Medical Center, Durham, NC

Clinical Cardiology Fellowship (2015–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

ACC Accreditation Foundation Board Quality Initiative Award (2019): Awarded with Co-Fellow Jennifer Rymer grant funding for project titled The Duke Renal Impairment Project (DRIP) Initiative. Provides \$83,681.09 of funding to support this project. PI is Dr. Sunil Rao.

NIH Loan Repayment Program Award (2018–present): Chosen for two years of funding during clinical research time. Award money applied toward student loan debt in a total of \$70,000.

NIH T32 Training Grant (2018–2019): Received salary support from the Division of Cardiology Institutional Training Award.

### Quantitative Training

Clinical Research Training Program, Masters of Health Sciences in Clinical Research (August 2017–present): Duke University School of Medicine, Durham, NC

## SAMIA ALEEM, MD

### Training

Medical School (2006–2011): Jinnah Sindh Medical University, Karachi, Pakistan

Pediatric Residency (2014–2017): Einstein Medical Center, Philadelphia, PA

Neonatal-Perinatal Medicine Fellowship (2017–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2018–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

Duke Pediatric Research Scholar (2017–present)

Southeastern Association of Neonatology Trainee Travel Grant (2019)

### Quantitative Training

Clinical Research Training Program, Masters of Health Sciences in Clinical Research (August 2018–present)  
Duke University School of Medicine, Durham, NC. Anticipated degree in 2020.

## LAURA BECH, MD

### Training

Medical School (2011–2017): Aalborg University, Aalborg, Denmark

Radiology, Locum Doctor (2015–2016): Aalborg University Hospital, Aalborg, Denmark

Pediatric Residency (2017): Vendsyssel Regional Hospital, Hjørring, Denmark

Emergency and Acute Residency (2017–2018): Aalborg University Hospital, Aalborg, Denmark

General Practice Residency (2018): The North Denmark Region, Aalborg, Denmark

Clinical Research Fellow (2018–present): Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark

Clinical Research Fellow (2018–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

Research Scholarship (2016): Department of Pediatrics, The North Denmark Region, Aalborg, Denmark

Rosalie Petersens Fond (2018): Grant

Kong Christian den Tiendes Fond (2018): Grant

Knud og Edith Eriksens Mindefond (2018): Grant

Region Nordjyllands Forskningsfond, (2018): Grant

## FREDERIK DALGAARD, MD

### Training

Medical School (2008–2015): University of Copenhagen, Copenhagen, Denmark

Residency (2015–2016): Bispebjerg Hospital, Copenhagen, Denmark

Clinical Assistant (2016–present): Division of Cardiology, Herlev and Gentofte Hospital, Copenhagen, Denmark

Clinical Research Fellowship (2018–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

Danish Heart Foundation (2016–2019): Received salary support.

Gangstedfonden (2019–present): Received salary support.

FUKAP grant (2016–2018): Received salary support.

Travel grants from Knud Højgaard Fond 2018, Torben & Alice Frimodt Fond 2018, Danish Heart Foundation 2017, Danish Heart Foundation 2018

DCRI Cardiovascular/Metabolic Investing in Innovation Award (2018)

### Quantitative Training

Doctor of Philosophy in Clinical Research (2016–present): University of Copenhagen, Copenhagen, Denmark

## **DANIEL EDMONSTON, MD**

### **Training**

Medical School (2009–2013): Mercer University School of Medicine, Macon, GA

Internal Medicine Residency (2013–2016): New York-Presbyterian/Weill Cornell, New York, NY

Nephrology Fellowship, Clinical Investigator Pathway (2016–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

### **Awards/Grants**

2nd Place, National Kidney Foundation Young Investigators' Forum

2nd Place, Southern Society of Clinical Investigation Young Investigators' Forum

### **Quantitative Training**

Clinical Research Training Program (degree anticipated May 2020)

## **MARAT FUDIM, MD**

### **Training**

Medical School (2005–2011): University of Düsseldorf, Germany

Medicine Residency (2012–2015): Vanderbilt University Internal Medicine, Nashville, TN

Clinical Cardiology Fellowship (2015–2017): Duke University, Durham, NC

Clinical Research Fellowship (2017–2019): Duke Clinical Research Institute, Durham, NC

Innovation MD Fellow (2017–2018): Duke University, Durham, NC

### **Awards/Grants**

NIH T32 Training Grant (2017–2019): Received salary support from the Division of Cardiology Institutional Training Award.

AHA Mentored Research Fellow Grant, \$154,000 (2016–2018): Neuromodulation in Heart Failure. Marat Fudim, MD, is the PI.

Translate Duke Health Award, \$100,000 (2018): Splanchnic Nerve Block for Chronic Heart Failure. Marat Fudim, MD, is the co-PI.

Mario Foundation Award, \$35,000 (2018): Congestion Phenotype in Heart Failure. Marat Fudim, MD, is the PI.

### **Quantitative Training**

Clinical Research Training Program, Masters of Health Sciences in Clinical Research (May 2019): Duke University School of Medicine, Durham, NC

## **SARAH GOLDSTEIN, MD**

### **Training**

Medical School (2009–2013): University of North Carolina – Chapel Hill, Chapel Hill, NC

Internal Medicine Residency (2013–2016): Duke University Medical Center, Durham, NC

Clinical Cardiology Fellowship (2016–2020): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2018–2020): Duke Clinical Research Institute, Durham, NC

### **Awards/Grants**

NIH T-32 Training Grant (2018–2020): Received salary support from the Division of Cardiology Institutional Training Award.

## **BRIGID GRABERT, JD, MPH**

### **Training**

Law School (2007–2010): University of North Carolina School of Law, Chapel Hill, NC

Master of Public Health (2010–2011): UNC Gillings School of Public Health, Chapel Hill, NC

Doctor of Philosophy (2015–present): UNC Gillings School of Public Health, Chapel Hill, NC (expected in 2019)

Predocctoral Fellowship (2017–2019): Duke Clinical Research Institute, Department of Population Health Sciences, Durham, NC

### **Awards/Grants**

T32 Training Grant, UNC Lineberger Cancer Control Education Program Postdoctoral Fellowship (2019)

UNC Graduate School Graduate Student Transportation Grant (2018)

UNC Gillings School of Global Public Health Department of Health Policy and Management Travel Award (2018)

Duke Department of Population Health Travel Award (2018)

**Training**

Medical School (2008–2012): Northwestern University Feinberg School of Medicine, Chicago, IL

Internal Medicine Residency (2012–2015): McGaw Medical Center of Northwestern University, Chicago, IL

Clinical Cardiology Fellowship (2015–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

**Awards/Grants**

NIH T32 Training Grant (2017–2019): Salary from the Division of Cardiology Institutional Training Award.

Heart Failure Society of America/Emergency Medicine Foundation Acute Heart Failure Young Investigator Award, \$80,000 for one year (2017–2018): Comparison of Dyspnea Measurement Instruments in Acute Heart Failure (DYS-PNEA-AHF)

Duke Clinical Research Institute Executive Director Pathway Award, \$15,000 (2017–2018): Representativeness of an Acute Heart Failure Trial by Race and Sex: Results from a Joint Analysis of the ASCEND-HF Trial and the GWTG-HF Registry

**Training**

Medical School (1993–1999): University of La Laguna, Spain

Internal Medicine Residency (2000–2005): University Hospital of Gran Canaria Dr. Negrin, Las Palmas, Spain

Internal Medicine Internship & Residency (2013–2015): University of Arkansas for Medical Sciences, Little Rock, AR

Clinical Fellowship (2015–2017): Duke University

Transplant Infectious Diseases Fellowship (2017–2019): Duke University

Clinical Research Fellowship (2017–2019): Duke Clinical Research Institute

**Awards/Grants**

T32 Interdisciplinary Transplant Infectious Diseases Training Grant (2016–ongoing)

Transplant Center Award to study CMV in kidney transplant recipients (2019)

Supplemental funding through the DCRI (2-19): Prescribing Patterns Before and After Market Entry of a New Formulation Of Tenofovir. Awarded to Anna Hung (Lead Fellow). Marion Hemmerbach-Miller is acting as Co-lead Fellow.

Top 3 finalist case in Antimicrobial Resistance Clinical Case Challenge Contest; sponsorship to attend the AMR Symposium at the London School of Hygiene and Tropical Medicine (November 2018)

**Quantitative Training**

Clinical Research Training Program Certificate (May 2017): Duke University School of Medicine, Durham, NC

## **ANNA HUNG, PharmD, PHD, MS**

### **Training**

Doctor of Pharmacy (2010–2014): University of Maryland School of Pharmacy, Baltimore, MD

Master of Science in Pharmaceutical Health Services Research: University of Maryland School of Pharmacy, Baltimore, MD

Doctor of Philosophy in Pharmaceutical Health Services Research (2014–2018): University of Maryland School of Pharmacy, Baltimore, MD

### **Awards/Grants**

Duke Clinical Research Institute Executive Director's Pathway for Supplemental Funding Award, amount \$11,250

## **TAKU INOHARA, MD, PhD**

### **Training**

Medical School (2001–2007): Tohoku University School of Medicine, Sendai, Japan

Residency (2007–2010): St. Luke's International Hospital, Tokyo, Japan

Clinical Cardiology Fellowship (2010–2012): St. Luke's International Hospital, Tokyo, Japan

Advanced Interventional Fellowship (2012–2015): Keio University Hospital, Tokyo, Japan

Clinical Research Fellowship (2016–2019): Duke Clinical Research Institute, Durham, NC

### **Awards/Grants**

Boston Scientific-Duke University Strategic Alliance in Research Program (BS STAR) (2018–2019): Research grant

Kanae Foundation for the Promotion of Medical Science (2018–2019): Research grant

JSPS Overseas Research Fellowship (2017–2019): Received salary support.

### **Quantitative Training**

Coursework in Clinical Research Training Program, Duke University School of Medicine

## **OLIVER JAWITZ, MD**

### **Training**

Medical School (2011–2016): Yale School of Medicine, New Haven, CT

Residency (2016–present): General Surgery, Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2018–present): Duke Clinical Research Institute, Durham, NC

### **Awards/Grants**

NIH T32 Training Grant (2017–2018): Received salary support from the Division of Cardiology Institutional Training Award.

Southern Thoracic Surgical Association (STSA) James W. Brooks Resident Scholarship, Finalist

## **KARAN KUMAR, MD**

### **Training**

Medical School (2008–2012): The Johns Hopkins University School of Medicine, Baltimore, MD

Pediatric Residency (2012–2015): Stanford University Medical Center, Palo Alto, CA

Clinical Pediatric Critical Care Medicine Fellowship (2016–2019): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–2019): Duke Clinical Research Institute, Durham, NC

### **Awards/Grants**

UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program (2018–2019)

Duke Pediatric Research Scholar (2017–2019)

### **Quantitative Training**

Master of Science in Biostatistics (May 2019): Duke University School of Medicine, Durham, NC

## ZAK LORING, MD

### Training

Medical School (2008–2013): Duke University School of Medicine, Durham, NC

Residency (2013–2016): University of California, San Francisco, San Francisco, CA

Clinical Fellowship (2016–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2018–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

Executive Director's Pathway to Research Funding Award (2019–2020): Received project support for Advanced Electrocardiographic Predictors of Cardiac Resynchronization Therapy Response and Clinical Outcomes, Duke Clinical Research Institute, Durham, NC.

Boston Scientific-Duke Strategic Alliance for Research Award (2018–2019): Received project support for ECG Predictors of Pacemaker Induced Cardiomyopathy, Boston Scientific, Marlborough, MA.

### Quantitative Training

Clinical Research Training Program, Masters of Health Sciences in Clinical Research (anticipated Sept 2019): Duke University School of Medicine, Durham, NC.

## ANGELA LOWENSTERN, MD

### Training

Medical School (2008–2012): University of Michigan, Ann Arbor, MI

Internal Medicine Residency (2012–2015): Duke University Medical Center, Durham, NC

Clinical Cardiology Fellowship (2015–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

ACC Accreditation Foundation Board Quality Initiative Award (2019): Awarded with Co-Fellow Jennifer Rymer. Grant funding for project titled The Duke Renal Impairment Project (DRIP) Initiative. Provides \$83,681.09 of funding to support this project. PI is Dr. Sunil Rao.

NIH Loan Repayment Program Award (2018–present): Chosen for two years of funding during clinical research time. Award money applied toward student loan debt in a total of \$70,000.

NIH T32 Training Grant (2018–2019): Received salary support from the Division of Cardiology Institutional Training Award.

### Quantitative Training

Clinical Research Training Program, Master of Health Sciences in Clinical Research (August 2017–present): Duke University School of Medicine, Durham, NC

## **GUILLAUME MARQUIS-GRAVEL, MD**

### **Training**

Medical School (2005–2011): Université de Montréal, Montréal, Canada

Internal Medicine Residency (2011–2014): Université de Montréal, Montréal, Canada

Cardiology Fellowship (Dean’s Honour List) (2014–2017): Université de Montréal, Montréal, Canada

Interventional Cardiology Fellowship (2017–2018): Duke University, Durham, NC

Clinical Research Fellowship (2018–2020): Duke Clinical Research Institute, Durham, NC

### **Awards/Grants**

Duke Clinical Research Institute’s Executive Director Pathway Fellows Supplement Funding grant (2019): Received \$11,250 for “Analysis of the Prognostic Impact of Out-of-Hospital Bleeding Following Acute Coronary Syndromes on Time-Related Downstream Mortality.”

Canadian Institute of Health Research Fellowship Bursary (2018–2020): Salary support for two-year research fellowship at the DCRI.

Fonds de Recherche en Santé du Québec (FRQS) (2018–2020): Salary support for two-year research fellowship at the DCRI.

## **CHRISTOPHER MOSHER, MD**

### **Training**

Medical School (2010–2014): Indiana University School of Medicine, Indianapolis, IN

Internal Medicine Residency (2014–2017): Indiana University School of Medicine, Indianapolis, IN

Pulmonary and Critical Care Medicine Fellowship (2017–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2018–present): Duke Clinical Research Institute, Durham, NC

### **Quantitative Training**

Clinical Research Training Program, Master of Health Sciences in Clinical Research, anticipated May 2020: Duke University School of Medicine, Durham, NC

**Training**

Medical School (2008–2012): Stony Brook University School of Medicine, Stony Brook, NY

Internal Medicine Residency (2012–2015): Yale-New Haven Hospital, New Haven, CT

Internal Medicine Chief Residency (2015–2016): Yale-New Haven Hospital, New Haven, CT

Clinical Cardiology Fellowship (2016–2018): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2018–present): Duke Clinical Research Institute, Durham, NC

InnovateMD Fellow (2018–2019): Duke University, Durham, NC

**Awards/Grants**

NIH T32 Training Grant (2018–2020): Received salary support from the Division of Cardiology Institutional Training Award.

ACC/AGS/NIA Diagnostic Testing in Older Adults Travel Award (2018)

AHA EPI Early Career Travel Grant (2019)

Beaver Creek Fellows Program Travel Award (2019)

2019 ACC Scientific Sessions, Geriatric Cardiology Section, 1st Place Winning Abstract, Clinical/Translational (2019)

**Quantitative Training**

Clinical Research Training Program, Master of Health Sciences in Clinical Research (May 2019): Duke University School of Medicine, Durham, NC

## **ADAM NELSON, MD**

### **Training**

Medical School (2004–2010): University of Adelaide, South Australia

Intern Medical Officer (2011): Royal Adelaide Hospital, South Australia

Basic Physician Training (2012–2014): Royal Adelaide Hospital, South Australia

Cardiology Advanced Training (2015–2017): Royal Adelaide Hospital, South Australia

### **Awards/Grants**

Royal Australian College of Physicians: Travelling Fellowship 2018

National Heart Foundation: Travelling Fellowship 2018

### **Quantitative Training**

Honors Bachelor of Medical Science (2007): University of Adelaide, South Australia

Doctor of Philosophy (2013–2018): University of Adelaide, South Australia

Clinical Research Fellowship (2018–2020): Duke Clinical Research Institute, Durham, NC

## **JASON ROTTER, PHD, MHS**

### **Training**

Doctor of Philosophy, Health Policy (2019): University of North Carolina, Chapel Hill, NC

Masters of Health Science (2012): Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Predocctoral Fellowship (2017–2019): Duke Clinical Research Institute, Durham, NC

### **Quantitative Training**

Completed PhD at UNC-Chapel Hill (April 2019)

**Training**

Medical School (2006–2011): Vanderbilt University Medical Center, Nashville, TN

Master of Business Administration (2009–2010): Vanderbilt University, Nashville, TN

Internal Medicine Residency (2011–2014): Duke University Medical Center, Durham, NC

Chief Residency, Duke Hospital (2015–2016): Duke University Medical Center, Durham, NC

Clinical Cardiology Fellowship (2015–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

**Awards/Grants**

Executive Director Pathway DCRI Funding (January 2019)

Internal research funding (\$11,250) for work on “Understanding Racial Disparities in Invasive MI Management for Patients with Acute Myocardial Infarction and Chronic Kidney Disease”

BD-STAR Research Grant, Joint Collaboration between Boston Scientific & Duke University (November 2018)

One-year research support (\$56,000) for work on Comparative Effectiveness of Left Atrial Appendage Closure versus Under-dosed Anticoagulation for Patients with Non-Valvular Atrial Fibrillation.

American College of Cardiology Foundation Process Improvement Grant (March 2019)

Funding of \$83,681 for the Duke Renal Impairment Initiative to reduce contract nephropathy in the Duke Cardiac Cath Lab

DCRI Robert Harrington Award for Excellence in Clinical Research (May 2019)

**Quantitative Training**

Clinical Research Training Program, Master of Health Sciences in Clinical Research (May 2017–present): Duke University School of Medicine, Durham, NC

## APARNA SWAMINATHAN, MD

### Training

Medical School (2008–2012): Case Western Reserve University, Cleveland, OH

Internal Medicine Residency (2012–2015): Duke University Medical Center, Durham, NC

Internal Medicine Chief Resident (2016–2017): Duke University Medical Center, Durham, NC

Clinical Pulmonary/Critical Care Fellowship (2015–present): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–present): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

NIH T32 Training Grant (2014-2016): Received salary support from the Pulmonary Division Institutional Training Award.

American Thoracic Society Abstract Scholarship (2018)

### Quantitative Training

Clinical Research Training Program, Master of Health Sciences in Clinical Research (May 2019): Duke University School of Medicine, Durham, NC

## NATHAN WALDRON, MD, MHSc

### Training

Medical School (2008–2012): Duke University School of Medicine, Durham, NC

Internship, Transitional (2012–2013): Duke University Medical Center, Durham, NC

Residency, Anesthesiology (2013–2016): Duke University Medical Center, Durham, NC

Academic Career Enrichment Scholars (ACES) Program (2013–2016)

Fellowship, Adult Cardiothoracic Anesthesiology (2016–2017): Duke University Medical Center, Durham, NC

Fellowship, Critical Care Medicine (2017–2018): Duke University Medical Center, Durham, NC

Clinical Research Fellowship (2017–2019): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

American Heart Association (AHA) Mentored Clinical & Population Research Award (MCPRP), \$154,000 (July 2016-June 2019): “Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery.” The purpose of this randomized, controlled pilot study is to examine the effects of temporary cardiac parasympathetic blockade on atrial fibrillation and systemic inflammation after cardiac surgery. Role: PI. Mentor: Joseph Mathew.

### Quantitative Training

Master of Health Sciences, Clinical Investigation (2010–2016): Duke University School of Medicine, Durham, NC

Master of Science, Data Science (2018–present; expected in 2021): Duke University Graduate School, Durham, NC

## DAVID A. WILLIAMS, MD, MPH

### Training

Medical School (2009–2013): SUNY Downstate College of Medicine, Brooklyn, NY

Anesthesiology Residency – Perioperative (2013–2017): SUNY Downstate Medical Center, Brooklyn, NY

Medicine Fellowship – Clinical Research (2017–2018): Duke University Medical Center, Durham, NC

Fellowship (2018–current): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

NIH T32 Career Development Award (2018–present)

## MICHEL ZEITOUNI, MD

### Training

Université de Paris Ouest, Versailles, France (2007–2013)

Assistance-Publique Hôpitaux de Paris, Sorbonne University (2013–2018)

Research Fellow (2016–2017): INSERM UMRS1166 Thrombosis & Hemostasis

Fellowship (November 2018–November 2019 [expected]): Duke Clinical Research Institute, Durham, NC

### Awards/Grants

Fédération Française de Cardiologie (November 2018): Grant

Societe Francaise de Cardiologie (January 2019): Best Thesis Award

- 1 **Aleem S**, Greenberg RG. When to include a lumbar puncture in the evaluation for neonatal sepsis. *Neoreviews*. 2019;20(3):e124-e134.
- 2 Abuali M, Zivot A, Guerguis S, Valladares E, **Aleem S**, Gonzalez-Salazar F, Rouchou B, Mottola N, Braitman L, Paoletti, A. Outpatient antibiotic prescribing patterns in pediatric academic and community practices. *Am J Infect Control*. 2019. E-pub ahead of print.
- 3 **Bech LF**, Polcwiartek C, Kragholm K, Rohde C, Torp-Pedersen C, Nielsen J, Hagstrøm S. In utero exposure to antiepileptic drugs and learning disabilities in offspring: a nationwide register-based case-cohort study. *J Neurol Neurosurg Psychiatry*. 2019;89(12):1324-1331.
- 4 **Bech LF**, Donneborg M, Lund AL, Ebbesen F. Extreme neonatal hyperbilirubinemia, acute bilirubin encephalopathy and kernicterus spectrum disorders in children with galactosemia. *Pediatr Res*. 2018;84(2):228-232.
- 5 Costantino G, Ruwald MH, Quinn J, Camargo CA, **Dalgaard F**, Gislason G, et al. Prevalence of pulmonary embolism in patients with syncope. *JAMA Intern Med*. 2018;178(3):356-362.
- 6 **Dalgaard F**, Ruwald MH, Lindhardt TB, Gislason GH, Torp-Pedersen C, Pallisgaard JL. Patients with atrial fibrillation and permanent pacemaker: temporal changes in patient characteristics and pharmacotherapy. *Ai T*, editor. *PLoS One*. 2018;13(3):e0195175.
- 7 Fudim M, **Dalgaard F**, Fathallah M, Iskandrian AE, Borges-Neto S. Mechanical dyssynchrony: how do we measure it, what it means, and what we can do about it? *J Nuci Cardiol*. 2019. (E-pub ahead of print) PMID: 31144228
- 8 **Dalgaard F**, Pallisgaard JL, Lindhardt TB, Torp-Pederson C, Gislason GH, Ruwald MH. Rate and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia. *Heart Rhythm*. 2019. E-pub ahead of print.
- 9 Bondonno NP, **Dalgaard F**, Kyrø C, Murray K, Bondonno CP, Lewis JR, Croft KD, Gislason GH, Scalbert A, Cassidy A, Tjønneland A, Overvad K, Hodgson JM. Flavonoid intake is associated with lower mortality in the Danish Diet, Cancer, and Health Cohort. *Nature Communications*. 2019. In press. \*Joint 1st authorship.
- 10 Hein AM, Scialla JJ, **Edmonston D**, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. *JACC Heart Fail*. 2019;7(5):382.
- 11 **Edmonston DL**, Wu J, Matsouaka RA, Yancy C, Heidenreich P, Pina IL, Hernandez A, Fonarow GC, DeVore AD. Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. *Am Heart J*. 2019;212:101-112.
- 12 **Edmonston D**, Wolf M. Good guys, bad guys, guesses, and near misses in nephrology. *Clin J Am Soc Nephrol*. 2019;14(1):7-9.
- 13 **Edmonston D**, Morris, JD, Middleton, JP: Working toward an improved understanding of chronic cardiorenal syndrome Type 4. *Adv Chronic Kidney Dis*. 2018;25:454-467.
- 14 **Edmonston D**, Wolf M, Pencina M. Statins at dialysis transition-supportive but not sufficient. *JAMA Netw Open*. 2018;1:e182411.
- 15 McHugh KR, DeVore AD, Mentz RJ, **Edmonston D**, Green JB, Hernandez AF. The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: a focus on cardiorenal outcomes. *Clin Cardiol*. 2018;41(9):1259-1267.

- 16 Carlisle MA, **Fudim M**, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. *JACC Heart Fail.* 2019;7(6):447-456.
- 17 Hohnloser SH, **Fudim M**, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wellentin L, Granger CB, Lopes RD. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. *Circulation.* 2019;139(20):2292-2300.
- 18 Alenezi F, **Fudim M**, Rymer J, Dunning A, Chiswell K, Swaminathan M, Bottiger B, Velagapudi P, Nicoara A, Kisslo J, Velazquez E, Vemulapalli S, Bloomfield GS, Samad Z. Predictors and changes in cardiac hemodynamics and geometry with transcatheter aortic valve implantation. *Am J Cardiol.* 2019;123(5):813-819.
- 19 Ambrosy AP, Parzynski CS, Friedman DJ, **Fudim M**, Hernandez AF, Fonarow GC, Masoudi FA, Al-Khatib SM. Is time from last hospitalization from heart failure to placement of a primary prevention implantable cardioverter-defibrillator associated with patient outcomes? *Circulation.* 2018;138(24):2787-2797.
- 20 Ambrosy AP, Lewis GD, Malhotra R, Jones AD, Greene SJ, **Fudim M**, Coles A, Butler J, Sharma A, Hernandez AF, Mentz RJ. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF Trial. *J Cardiovasc Med.* 2019;20(4):223-225.
- 21 Ambrosy AP, Cerbin LP, **Fudim M**, Clare RM, Lokhnygina Y, Braunwald E, Califf RM, Cannon CP, Tershakovac AM, Roe MT, Blazing MA. Natural history of patients postacute coronary syndrome based on heart failure status. *Am J Cardiol.* 2018;122(9):1451-1458.
- 22 Waldron NH, Cooter M, Haney JC, Schroder JN, Gaca JG, Lin SS, Sigurdsson MI, **Fudim M**, Podgoreanu MV, Stafford-Smith M, Milano CA, Piccini JP, Matthew JP. Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery. *Heart Rhythm.* 2016;16(2):178-184.
- 23 Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, **Fudim M**, Böhm M, Maggioni AP, Lewis EF, Zannad F, Butler J. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. *Eur J Heart Fail.* 2018;20(12):1760-1763.
- 24 Kleiner Shochat M, **Fudim M**, Shotan A, Blondheim DS, Kazatsker M, Dahan I, Asif A, Rozenman Y, Kleiner I, Weinstein JM, Panjrath G, Sobotka PA, Meisel SR. Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial. *ESC Heart Fail.* 2018;5(5):788-799.
- 25 **Fudim M**, Ambrosy AP, Sun JL, Anstrom KJ, Bart BA, Butler J, AbouEzzedine O, Greene SJ, Mentz RJ, Redfield MM, Reddy YNV, Vaduganathan M, Braunwald E, Hernandez AF, Borlaug BA, Felker GM. High sensitivity troponin I in hospitalized and ambulatory patients with heart failure with preserved ejection fraction: insights from the Heart Failure Clinical Research Network. *J Am Heart Assoc.* 2018;7(24):e010364.
- 26 **Fudim M**, Jones WS. New curveball for hypertension guidelines? *Circulation.* 2018;138(17):1815-1818.
- 27 **Fudim M**, Parikh KS, Dunning A, DeVore AD, Mentz RJ, Schulte PJ, Armstrong PW, Ezekowitz JA, Tang WHW, McMurray JJV, Voors AA, Drazner MH, O'Connor CM, Hernandez AF, Patel CB. Relation of volume overload to clinical outcomes in acute heart failure (from ASCEND-HF). *Am J Cardiol.* 2018;122(9):1506-1512.
- 28 **Fudim M**, O'Connor CM, Mulder H, Coples A, Bhatt AS, Ambrosy AP, Kraus WE, Pina IL, Whellan DJ, Mentz RJ. Loop diuretic adjustments in patients with chronic heart failure: insights from HF ACTION. *Am Heart J.* 2018;205:133-141.

- 29 **Fudim M**, Ganesh A, Green C, Jones WS, Blazing MA, DeVore AD, Felker GM, Kiefer TL, Kong DF, Boortz-Marx RL, Hernandez AF, Patel MR. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. *Eur Heart J*. 2018;39(48):4255-4256.
- 30 **Fudim M**, Loungani R, Doerfler SM, Coles AQ, Greene SJ, Cooper LB, Fiuzat M, O'Connor CM, Rogers JG, Mentz RJ. Worsening renal function during decongestion among patients hospitalized for heart failure: findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial. *Am Heart J*. 2018;204:163-173.
- 31 **Fudim M**, Miller WL. Calculation estimates of plasma volume in patients with chronic heart failure comparison with measured volumes. *J Card Fail*. 2018;24(9):553-560.
- 32 **Fudim M**, Eng M, Sobotka PA. Transcatheter renal denervation for resistant hypertension. In Topol E, Teirstein P, editors. *Textbook of Interventional Cardiology*. 8th ed. Elsevier 2018.
- 33 **Fudim M**, Dalgaard F, Fathallah M, Iskandrian AE, Borges-Neto S. Mechanical dyssynchrony: how do we measure it, what it means, and what we can do about it. *J Nucl Cardiol*. 2019. (E-pub ahead of print) PMID: 31144228
- 34 **Fudim M**, Borges-Neto S. Moving towards a synchronized left ventricle. *J Nucl Cardiol*. 2019. E-pub ahead of print. PMID: 31087264
- 35 **Goldstein SA**, Mentz RJ, Hellkamp AS, Randolph TC, Fonarow GC, Hernandez A, Yancy CW, Al-Khatib SM. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. *Clinical Cardiol*. 2019;42(2):256-263.
- 36 Gertner AK, **Grabert BK**, Domino ME, Cuddeback GS, Morrissey JP. The effect of expedited Medicaid on substance use treatment utilization among people with severe mental illness released from prison. *Journal of Substance Abuse Treatment*. 2019 Jan 11.
- 37 Domino ME, Gertner AK, **Grabert BK**, Cuddeback GS, Childers T, Morrissey JP. Do timely mental health services reduce recidivism among prison releases with severe mental illness? *Health Services Research*. 2019;54(3):592-602.
- 38 Alkhawam L, **Greene SJ**. Bulletproof heart: gunshot wound to the ventricular septum without pericardial effusion or hemodynamic collapse. *CJEM*. 2018;20(S2):S40.
- 39 Njoroge JN, Cheema B, Ambrosy AP, **Greene SJ**, Collins SP, Vaduganathan M, Mebazaa A, Chioncel O, Butler J, Gheorghiade M. Expanded algorithm for managing patients with acute decompensated heart failure. *Heart Fail Rev*. 2018;23(4):597-607.
- 40 Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, **Greene SJ**, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, Butler J, Gheorghiade M, Zannad F. Sudden death following hospitalization for heart failure with reduced ejection fraction (from the EVEREST trial). *Am J Cardiol*. 2018;122(2):255-260.
- 41 Iorio A, Senni M, Barbati G, **Greene SJ**, Poli S, Zambon E, Di Nora C, Cioffi G, Tarantini L, Gavazzi A, Sinagra G, Di Lenarda A. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. *Eur J Heart Fail*. 2018;20(9):1257-1266.
- 42 **Greene SJ**, Felker GM. Innovation in diuretic therapy: the missing ingredient for treating worsening heart failure outside the hospital? *JACC Basic Transl Sci*. 2018;3(1):35-37.
- 43 **Greene SJ**, O'Brien EC, Mentz RJ, Luo N, Hardy NC, Laskey WK, Heidenreich PA, Chang CL, Turner SJ, Yancy CW, Hernandez AF, Curtis LH, Peterson PN, Fonarow GC, Hammill BG. Home-time after discharge among patients with heart failure. *J Am Coll Cardiol*. 2018;71(23):2643-2652.

- 44 Patel RB, Vaduganathan M, **Greene SJ**, Butler J. Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. *Eur J Heart Fail.* 2018;20(9):1379-1381.
- 45 Mentz RJ, **Greene SJ**. Adding troponin to the puzzle of heart failure with preserved ejection fraction: marker or mediator? *J Am Coll Cardiol.* 2018;72(1):41-44.
- 46 Samman Tahhan A, Vaduganathan M, Kumar S, Okafor M, **Greene SJ**, Butler J. Design elements and enrollment patterns of contemporary trials in heart failure with preserved ejection fraction: a systematic review. *JACC Heart Fail.* 2018;6(8):714-717.
- 47 **Greene SJ**, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. *J Am Coll Cardiol.* 2018;72(4):351-366.
- 48 Fudim M, Loungani R, Doerfler SM, Coles A, **Greene SJ**, Cooper LB, Fuizat M, O'Connor CM, Rogers JG, Mentz RJ. Worsening renal function during decongestion among patients hospitalized for heart failure: findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. *Am Heart J.* 2018;204:163-173.
- 49 Tahhan A, Vaduganathan M, **Greene SJ**, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O'Connor CM, Butler J. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. *JAMA Cardiol.* 2018;3(10):1011-1019.
- 50 **Greene SJ**, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM. Reassessing the role of surrogate end points in drug development for heart failure. *Circulation.* 2018;138:1039-1053.
- 51 **Greene SJ**, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ. Relationship between enrolling country income level and patient profile, protocol completion, and trial end points: from the ASCEND-HF trial. *Circ Cardiovasc Qual Outcomes.* 2018;11(10):e004783.
- 52 **Greene SJ**, Felker GM, Butler J. Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. *Eur J Heart Fail.* 2019;21(1):121-124.
- 53 Patel RB, Vaduganathan M, Rikhi A, Chakraborty H, **Greene SJ**, Hernandez AF, Felker GM, Redfield MM, Butler J, Shah SJ. History of atrial fibrillation and trajectory of decongestion in acute heart failure. *JACC Heart Fail.* 2019;7(1):47-55.
- 54 Bhagat AA, **Greene SJ**, Vaduganathan M, Fonarow GC, Butler J. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. *JACC Heart Fail.* 2019;7(1):1-12.
- 55 **Greene SJ**, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Böhm M, Maggioni AP, Lewis EF, Zannad F, Butler J. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. *Eur J Heart Fail.* 2018;20(12):1760-1763.
- 56 Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, **Greene SJ**, Ahmed A, Januzzi JL, Gheorghiu M, Filippatos G, Butler J. Medication dosing for heart failure with reduced ejection fraction – opportunities and challenges. *Eur J Heart Fail.* 2019;21(3):286-296.
- 57 Ambrosy AP, Lewis GD, Malhotra R, Jones AD, **Greene SJ**, Fudim M, Coles A, Butler J, Sharma A, Hernandez AF, Mentz RJ. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. *J Cardiovasc Med.* 2019;20(4):223-225.
- 58 Fudim M, Ambrosy AP, Sun JL, Anstrom KJ, Bart BA, Butler J, AbouEzzedine O, **Greene SJ**, Mentz RJ, Redfield MM, Reddy YNV, Vaduganathan M, Braunwald E, Hernandez AF, Borlaug BA, Felker GM.

- High-sensitivity troponin I in hospitalized and ambulatory patients with heart failure with preserved ejection fraction: insights from the Heart Failure Clinical Research Network. *J Am Heart Assoc.* 2018;7(24):e010364.
- 59 Friedman DJ, **Greene SJ**, Piccini JP, Vemulapalli S, Jackson KP. Watchman implantation in a patient with left atrial appendage thrombus. *J Cardiovasc Electrophysiol.* 2019. E-pub ahead of print.
- 60 **Greene SJ**, Felker GM. The urgency of doing: addressing gaps in use of evidence-based medical therapy for heart failure. *JACC Heart Fail.* 2019;7(24):22-24.
- 61 **Greene SJ**, Butler J. Primary prevention of heart failure in patients with type 2 diabetes mellitus. *Circulation.* 2019;139(2):152-154.
- 62 **Greene SJ**, Califf RM. Reframing global variation in heart failure trials: thinking beyond location on the map. *JACC Heart Fail.* 2019;7(4):347-349.
- 63 Eisenstein EL, Prather K, **Greene SJ**, Harding T, Harrington A, Gabriel D, Jones I, Mentz RJ, Velazquez EJ, Anstrom KJ. Death: the simple clinical trial endpoint. *Stud Health Technol Inform.* 2019;257:86-91.
- 64 Vaduganathan M, Tahhan AS, Alrohaibani A, **Greene SJ**, Fonarow GC, Vardeny O, Lindenfeld J, Jessup M, Fiuzat M, O'Connor CM, Butler J. Do women and men respond similarly to therapies in contemporary heart failure clinical trials? *JACC Heart Fail.* 2019;7(3):267-271.
- 65 **Greene SJ**, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. *J Am Coll Cardiol.* 2019;73(19):2365-2383.
- 66 **Greene SJ**, Wilson LE, Abbasi SA, Yusuf AA, Hammill BG. Outpatient intravenous diuretic therapy for heart failure in the United States. *J Am Coll Cardiol.* 2019;73(9):1101-1103.
- 67 Psotka MA, Ammon SE, Fiuzat M, Bozkurt B, Chung ES, Cole RT, **Greene SJ**, Kraus D, Ky B, McIlvennan CK, Shah P, Teerlink JR, Walsh MN, Jessup M, O'Connor CM. Heart failure site-based research in the United States: results from the Heart Failure Society of America Research Network Survey. *JACC Heart Fail.* 2019;7(5):431-438.
- 68 **Hemmersbach-Miller M**, Alexander BD, Sudan DL, Pieper C, Schmader KE. Infections after kidney transplantation. Does age matter? *Clin Transpl.* 2019;33(4):e13516. PMID: 30849194
- 69 **Hemmersbach-Miller M**, Wolfe C, Schmader K. Solid organ transplantation in older adults. Infectious and other age-related considerations. *OBM Transplantation.* 2019;3(1):19.
- 70 **Hemmersbach-Miller M**, Bailey ES, Kappus M, Prasad VK, Gray GC, Alspaugh JA. Disseminated adenovirus infection after combined liver-kidney transplantation. *Front Cell Infect Microbiol.* 2018;8:408.
- 71 **Hemmersbach-Miller M**, Alexander BD, Sudan DL, Pieper C, Schmader KE. Single center analysis of infectious complications in older adults during the first year after kidney transplantation. *Eur J Clin Microbiol Infect Dis.* 2019;38(1):141-148.
- 72 **Hemmersbach-Miller M**, Stout JE, Woodworth MH, Cox GM, Saullo JL. Nocardia infections in the transplanted host. *Transpl Infect Dis.* 2018;20(4):e12902.
- 73 **Hemmersbach-Miller M**, Berg C, Messina J, Wolfe C. Transplant drug interactions and a word of caution for the HIV provider. A case report. *Open Forum Infect Dis.* 2018;5(4):ofy070.
- 74 Messina J, Wolfe C, **Hemmersbach-Miller M**, Milano C, Todd JL, Reynolds J, Alexander BD, Shell WA, Cuomo CA, Perfect JR. Genomic characterization of recurrent mold infections in thoracic transplant recipients. *Transpl Infect Dis.* 2018;20(5):e12935.

- 75 **Hemmersbach-Miller M.** The right fit. HIV-positive solid organ transplant recipient and donor suitability. *HIV Specialist*. Journal from the American Academy of HIV Medicine (AAHIVM). 2018 Jul. Available from: [https://aahivm.org/wp-content/uploads/2018/07/FINALHIVspecialist\\_July2018FINAL-1.pdf](https://aahivm.org/wp-content/uploads/2018/07/FINALHIVspecialist_July2018FINAL-1.pdf)
- 76 **Hung A, Gedey R, Groeneweg M, Jay M.** A primer for managed care residents: How to conduct research using live medical and pharmacy claims data. *J Manag Care Spec Pharm*. 2019;25(5):538-543.
- 77 **Hung A, Mullins CD, Slejko JF, Haines ST, Shaya F, Lugo A.** Using a budget impact model framework to evaluate antidiabetic formulary changes and utilization management tools. *J Manag Care Spec Pharm*. 2019 Mar;25(3):342-349.
- 78 **Doshi P, Sieluk J, Hung A.** The possible harms of statins: what do product labels, patient package inserts, and pharmacy leaflets tell us? *J Am Pharm Assoc*. 2019;59(2):195-201.
- 79 **Inohara T, Pieper K, Wojdyla DM, Patel MR, Jones WS, Tricoci P, Mahaffey KW, James SK, Alexander JH, Lopes RD, Wallentin L, Ohman EM, Roe MT, Vemulapalli S.** Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. *Am Heart J*. 2018;201:25-32.
- 80 **Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, Thourani VH, Carroll JD, Kirtane AJ, Bavaria JE, Cohen DJ, Kiefer TL, Gaca JG, Kapadia SR, Peterson ED, Vemulapalli S.** Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. *JAMA*. 2018 Apr;320(21):2231-2241.
- 81 **Inohara T, Vemulapalli S.** Transcatheter aortic valve replacement in the era of quality assessment. *Circ Cardiovasc Qual Outcomes*. 2018;11(12):e005233.
- 82 **Numasawa Y, Inohara T, Ishii H, Yamaji K, Kohsaka S, Sawano M, Kodaira M, Uemura S, Kadota K, Amano T, Nakamura M; J-PCI Registry Investigators.** Comparison of outcomes after percutaneous coronary intervention in elderly patients, including 10 628 nonagenarians: insights from a Japanese nationwide registry (J-PCI Registry). *J Am Heart Assoc*. 2019;8(5):e011183.
- 83 **Numasawa Y, Inohara T, Ishii H, Yamaji K, Hirano K, Kohsaka S, Sawano M, Kuno T, Kodaira M, Uemura S, Kodata K, Amano T, Nakamura M, J-PCI Registry Investigators.** An overview of percutaneous coronary intervention in dialysis patients: insights from a Japanese nationwide registry. *Catheter Cardiovasc Inter*. 2018 E-pub ahead of print. PMID: 30467967
- 84 **Inohara T, Ichihara N, Kohsaka S, Miyata H, Hirata Y, Murakami A, Shimizu H, Aeba R.** The effect of body weight in infants undergoing ventricular septal defect closure: a report from the Nationwide Japanese Congenital Surgical Database. *J Thrac Cardiovasc Surg*. 2019 Mar;157(3):1132-1141.
- 85 **Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED.** Blood pressure control and cardiovascular outcomes in patients with atrial fibrillation (from the ORBIT-AF Registry). *Am J Cardiol*. 2019;123(10):1628-1636.
- 86 **Inohara T, Endo A, Melloni C.** Unmet needs in managing myocardial infarction in patients with malignancy. *Front Cardiovasc Med*. 2019;6:57.
- 87 **Inohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.** *Am Heart J*. 2019;213:81-90.
- 88 **Inohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.** B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. *Heart*. 2018 Sep. E-pub ahead of print. PMID: 30228248

- 89 Numasawa Y, **Inohara T**, Ishii H, Yamaji K, Hirano K, Kohsaka S, Sawano M, Kuno T, Kodaira M, Uemura S, Kadota K, Amano T, Nakamura M; J-PCI Registry Investigators. An overview of percutaneous coronary intervention in dialysis patients: insights from a Japanese nationwide registry. *Catheter Cardiovasc Interv*. 2018. E-pub ahead of print. PMID: 30467967
- 90 Adam MA, Moris D, Behren S, Nussbaum D, **Jawitz OK**, Turner M, Lidsky M, Blazer D 3<sup>rd</sup>. Hospital volume threshold for the treatment of retroperitoneal sarcoma. *Anticancer Res*. 2019;39(4):2007-2014.
- 91 Raman V, **Jawitz OK**, Yang CJ, Yong BC, D'Amico TA, Berry MF, Harpole DH Jr. Adjuvant therapy for patients with early large cell lung neuroendocrine cancer: a national analysis. *Ann Thorac Surg*. 2019;39(4):2007-2014.
- 92 **Jawitz OK**, Raman V, Barac Y, Anand J, Patel C, Mentz R, Devore A, Milano C. Impact of donor brain death duration on outcomes following heart transplantation: a UNOS registry analysis. *J Thorac Cardiovasc Surg*. 2019. E-pub ahead of print. PMID: 31004586
- 93 **Jawitz OK**, Raman V, Barac YD, Anand J, Patel CB, Mentz RJ, DeVore AD, Milano C. Influence of donor brain death duration on outcomes following heart transplantation: a united network for organ sharing registry analysis. E-pub ahead of print. PMID: 31147170
- 94 Barac Y, Nevo A, **Jawitz OK**, Hashmi NK, Henkel P, Kelly J, Patel CB, Daneshmand MA, Schroder JN, Welsby I. Prothrombin complex concentrate use in durable and short term LVAD implantation. *ASAIO Journal*. 2019. E-pub ahead of print. PMID: 30688689
- 95 **Jawitz OK**, Adam MA, Turner MC, Gilmore BF, Migaly J. Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. *Surgery*. 2019. E-pub ahead of print. PMID: 30904173
- 96 **Jawitz OK**, Keenan J, Perna J, Milano C. Successful aneurysm resection and coronary artery revascularization following saphenous vein graft aneurysm rupture. *Eur J Cardiothorac Surg*. 2018. E-pub ahead of print. PMID: 30060015
- 97 **Kumar KR**, Clark DA, Kim EM, Perry JD, Wright K, Thomas SA, Thompson EJ, Greenberg RG, Smith PB, Benjamin DK Jr, Laughon MM, Clark RH, Hornik CP. Association of atrial septal defects and bronchopulmonary dysplasia in premature infants. *J Pediatr*. 2018;202:56-62.
- 98 Pelleter JH, **Kumar KR**, Engen R, Bensimhon A, Varner JD, Rheault MN, Srivastava T, Straatmann C, Silva C, Davis TK, Wenderfer SE, Gibson K, Selewski D, Barcia J, Weng P, Licht C, Jawa N, Kallash M, Foremann JW, Wigfall DR, Chua AN, Chambers E, Hornik CP, Brewer ED, Nagaraj SK, Greenbaum LA, Gbadegesin RA. Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy finding. *Nephrol*. 2018;33(10):1773-1780.
- 99 **Kumar KR**, Hornik CP. Commentary: singling out single ventricles after Fontan. *J Thorac Cardiovasc Surg*. 2019;157(5):2016-2017.
- 100 Thompson EJ, Greenberg RG, **Kumar K**, Laughon M, Smith PB, Clark RH, Crowell A, Shaw L, Harrison L, Scales G, Bell N, Hornick CP. Association between furosemide exposure and patent ductus arteriosus in hospitalized infants of very low birth weight. *J Pediatr*. 2018;199:231-236.
- 101 **Kumar KR**, Kirsch RE, Hornik CP. Cardiovascular physiology for intensivists. In: Ungerleider RM, Meliones JN, Nelson McMillan K, Cooper DS, Jacobs JP, editors. *Critical Heart Disease in Infants and Children*. 3rd ed. China: Elsevier. 2019:13.1-13.23.e5.
- 102 **Lentz TA**, Beneciuk JM, George SZ. Prediction of healthcare utilization following an episode of physical therapy for musculoskeletal pain. *BMC Health Serv Res*. 2018;18(1):648.
- 103 **Lentz TA**, Paterno MV, Riboh JC. So you think you can return to sport? *Br J Sports Med*. 2018;52(23):1482-1483.

- 104 **Lentz TA**, Rhon DI, George SZ. Predicting opioid use, increased health care utilization and high costs for musculoskeletal pain: what factors mediate pain intensity and disability? *J Pain*. 2019. E-pub ahead of print. PMID: 31201989
- 105 **Lentz TA**, Marlow NM, Beneciuk JM, Fillingim RB, George SZ. Comorbidity subgroups among Medicare beneficiaries seeking health care for musculoskeletal pain. *J Gerontol A Biol Sci Med Sci*. 2018. E-pub ahead of print. PMID: 30126409
- 106 Malay M, **Lentz TA**, O'Donnell J, Coles T, Mather III RC, Jiranek WA. Development and initial outcomes of a comprehensive, non-surgical joint health program for individuals with osteoarthritis: Administrative Case Report. *Phys Ther*. In press.
- 107 Rhon DI, Mysliwiec V, O'Hagan E, **Lentz TA**. Does disordered sleep moderate the relationship between pain, disability and downstream healthcare utilization in patients with low back pain? A longitudinal cohort from the US Military Health System. *Spine*. In press.
- 108 **Lowenstern A**, Lippmann SJ, Brennan JM, Wang TY, Curtis LH, Feldman T, Glower DD, Hammill BG, Vemulapalli S. Use of Medicare claims to identify adverse clinical outcomes after mitral valve repair. *Circ Cardiovasc Interv*. 2019;12(5):e007451.
- 109 Varshney AS, Manandhar P, Vemulapalli S, Kirtane AJ, Mathew V, Shah B, **Lowenstern A**, Kosinski AS, Kaneko T, Thourani VH, Bhatt DL. Left ventricular hypertrophy does not affect 1-year clinical outcomes in patients undergoing transcatheter aortic valve replacement. *JACC Cardiovasc Interv*. 2019;12(4):373-382.
- 110 **Lowenstern A**, Navar AM, Li S, Virani SS, Goldberg AC, Louie MJ, Lee LV, Peterson ED, Wang TY. Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels: a survey of US practice in the PALM Registry. *Am J Cardiol*. 2019;123(7):1011-1018.
- 111 **Lowenstern A**, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, Borre ED, Raitz G, Goode A, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Sanders G. Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review. *Ann Intern Med*. 2018;169:774-87.
- 112 Sanders GD, **Lowenstern A**, Borre E, Chatterjee R, Goode A, Sharan L, Allen LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S. Stroke prevention in patients with atrial fibrillation: a systematic review update. Comparative Effectiveness Review No 214. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2015-00004-I for AHRQ and PCORI) AHRQ Publication No. 18-EHC018-EF. Rockville, MD: Agency for Healthcare Research and Quality 2018. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm)
- 113 Borre E, Goode AP, Raitz G, Shah B, **Lowenstern A**, Chatterjee R, Sharan L, Allen LaPoint N, Yapa R, Davis J, Lallinger K, Schmidt R, Kosinski AS, Al-Khatib SM, Sanders GD. Predicting thromboembolic and bleeding event risk in patients with nonvalvular atrial fibrillation: a systematic review. *J Thromb Thrombolysis*. 2018;118(12):2171-87.
- 114 **Lowenstern A**, Li S, Navar AM, Roger VL, Robinson JG, Goldberg AC, Virani SS, Lee LV, Wilson PWF, Louie MJ, Peterson ED, Wang TY. Measurement of low-density lipoprotein cholesterol levels in primary and secondary prevention patients: insights from the PALM Registry. *JAHA*. 2018;7(18):e009251.
- 115 **Lowenstern A**, Vora AN, Dunning A, Schulte PJ, Vemulapalli S, Hughes GC, Velazquez EJ, Harrison JK, Samad Z. Transcatheter aortic valve replacement versus medical management among patients with aortic stenosis and left ventricular systolic dysfunction. *Structural Heart*. 2018;2(5):388-95.
- 116 **Lowenstern A**, Wang TY. Rethinking cognitive impairment in the management of older patients with cardiovascular disease. *J Am Heart Assoc*. 2019;8(4):e011968.

- 117 Newby LK, **Lowenstern A**. Implications of high sensitivity troponin testing: learning from those who came before us. *J Am Coll Cardiol*. 2018;71(23):2625-2627.
- 118 **Marquis-Gravel G**, Ohman EM. Left ventricular support: are two devices better than one? *Circulation: Cardiovascular Interventions*. 2018;11(9):e007214.
- 119 **Marquis-Gravel G**. What do patients expect from a transcatheter aortic valve replacement? The importance of considering meaningful non-mortality outcomes. *Can J Cardiol*. 2019;35(6):681-683.
- 120 Azzalini L, Chabot-Blanchet M, Southern DA, Nozza A, Wilton SB, Graham MM, **Marquis-Gravel GM**, Bluteau JP, Rouleau JL, Guertin MC, Jolicoeur EM. Disease-specific comorbidity indexes to predict mortality with administrative databases in patients hospitalized for a cardiac condition. *CMAJ*. 2019;191(11):299-307.
- 121 **Marquis-Gravel G**, Thiele H, Jones WS, Smalling RW, Cohen M, Perera D, Pijls N, Fanaroff A, Brucker A, Chiswell K, Patel MR, Ohman EM. Size of anterior wall acute myocardial infarction treated by primary percutaneous coronary intervention in United States versus Europe/Australia versus India (from the CRISP-AMI Randomized Controlled Trial). *Am J Cardiol*. 2019;123(7):1026-1034.
- 122 Tremblay-Gravel M, **Marquis-Gravel G**, Avram R, Desplantie O, Ducharme O, Bibas L, Pacheco C, Couture E, Simard F, Poulin A, Malhamé I, Tran D, Rey E, Tournoux F, Harvey L, Sénéchal M, Bélisle P, Descarries L, Farand P, Pranno N, Diaz A, Afilalo J, Ly HQ, Fortier A, Jolicoeur EM, on behalf of the BRO-HF investigators. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study. *ESC Heart Fail*. 2019;6(1):27-36.
- 123 Picard F, Avram R, **Marquis-Gravel G**, Tadros VX, Ly HQ, Dorval JF, Doucet S, Gosselin G, Asgar AW, Ibrahi R, Bonan R, de Hemptinne Q, Nosair M, L-L'Allier P, Tanguay JF. Clinical outcomes of bioresorbable vascular scaffolds to treat all-comer patients. Are patients with acute coronary syndromes better candidates for bioresorbable vascular scaffolds? *Cardiovascular Revascularization Medicine*. 2019;20(3):228-234.
- 124 **Loring Z**, Sun AY. Should His-bundle pacing be preferred over CRT following AHJ ablation? *Cardiol Clinics*. 2019;37(2):231-240.
- 125 **Loring Z**, Atwater BD, Xia X, Axelsson J, Klem I, Nijveldt R, Schelbert EB, Couderc JP, Strauss DG, Ugander M, Wieslander B. Low lead one ratio predicts clinical outcomes in left bundle branch block. *J Cardiovasc Electrophysiol*. 2019;30(5):709-716.
- 126 **Loring Z**, Friedman DJ, Sun AY, Atwater BD. Pitfalls in programming: the HV and VH intervals in his bundle pacing. *J Electrocardiol*. 2018;51(5):776-778.
- 127 **Loring Z**, Piccini JP. Atrial fibrillation and obstructive lung disease: don't fear the beta-blocker. *Heart Rhythm*. 2018;15(12):1833-1834.
- 128 **Loring Z**, Atwater BD. Harm from left bundle branch block: we are the tortoise, not the hare. *Trends Cardiovasc Med*. 2018. E-pub ahead of print. PMID: 30573034
- 129 **Loring Z**, Mehrotra S, Piccini JP. Machine learning in Big Data: handle with care. *Europace*. 2019. E-pub ahead of print. PMID: 31106325
- 130 **Loring Z**, Strauss DG, Schocken D, Daubert JP. Introduction to arrhythmias. *Marriott's Practical Electrocardiography*, 13th edition. Wolters Kluwer; 2019.
- 131 **Nanna MG**, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, Peterson ED, Navar AM. Sex differences in the use of statins in community practice: The PALM Registry. *Circ Cardiovasc Qual Outcomes*. In press.
- 132 **Nanna MG**, Navar AM, Wang TY, Li S, Virani SS, Li Z, Robinson JG, Roger VL, Wilson PWF, Goldberg AC, Koren A, Louie MJ, Peterson ED. Practice-level variation in statin use and LDL-C control

- in the United States: results from the Patient and Provider Assessment of Lipid Management (PALM) Registry. *Am Heart J.* 2019;214:113-124.
- 133 Alonso A, Anderson MD, Bancks MP, Brown SA, Caughey MC, Chang AR, Delker E, Foti K, Gingras V, **Nanna MG**, Razavi AC, Scott J, Selvin E, Tcheandjieu C, Thomas AG, Turkson-Ocran RAN, Webel A, Young DR, DeBarmore BM. Highlights from the American Heart Association's EPI|LIFESTYLE 2019 Scientific Sessions. *Journal of the American Heart Association.* 2019;8:e012925.
- 134 Dodson JA, Hajduk AM, Murphy TE, Geda M, Krumholz HM, Tsang S, **Nanna MG**, Tinetti ME, Goldstein D, Forman DE, Alexander KP, Gill TM, Chaudhry SI. Thirty-day readmission risk model for older adults hospitalized with acute myocardial infarction. *Circ Cardiovasc Qual Outcomes.* 2019;12(5):e005320.
- 135 **Nanna MG**, Navar AM, Zakrotsky P, Xiang Q, Goldberg AC, Robinson J, Roger VL, Virani SS, Wilson PWF, Elassal J, Lee LV, Wang TY, Peterson ED. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the Patient and Provider Assessment of Lipid Management Registry. *JAMA Cardiol.* 2018;3(8):739-748.
- 136 Granger CB, **Nelson AJ**, Pagidipati NJ. Risk of total events with icosapent ethyl: can we reduce it? *J Am Coll Cardiol.* 2019;73(22):2803-2805.
- 137 Nicholls SJ, **Nelson AJ**. Do cholesteryl ester transfer protein inhibitors have a role in the treatment of cardiovascular disease? *Am J Cardiovasc Drugs.* 2019;9(3):229-235.
- 138 Scherer DJ, **Nelson AJ**, O'Brien R, Kostner KM, Hare DL, Colquhoun DM, Barter PJ, Aylward P, Nicholls SJ, Watts GF. Status of PCSK9 monoclonal antibodies in Australia. *Heart Lung Circ.* 2019 May 8. pii: S1443-9506(19)30354-3.
- 139 Nicholls SJ, **Nelson AJ**. The time for lipoprotein(a) based intervention has arrived: where will the light shine? *J Thorac Dis.* 2019 Mar;11(Suppl 3):S433-S436.
- 140 **Nelson AJ**, Dundon BK, Worthley SG, Richardson JD, Puri R, Wong DTL, Coates PT, Faull RJ, Worthley MI. End-stage renal failure is associated with impaired coronary microvascular function. *Coron Artery Dis.* 2019 Mar 13.
- 141 **Nelson AJ**, Granger CB. In middle-aged adults, Astro-CHARM was better than a standard risk factor model for predicting 10-year ASCVD risk. *Ann Intern Med.* 2019;170(4):JC23.
- 142 **Nelson AJ**, Roberts-Thomson RL, Stokes MB, Baumann AA, Nicholls SJ. Pulsatile torso: Giant cardiomegaly from untreated tricuspid endocarditis. *Postgrad Med J.* 2019;95(1121):174.
- 143 Nicholls SJ, **Nelson AJ**. Monitoring the response to statin therapy: one scan at a time. *JACC Cardiovasc Imaging.* 2018;11(10):1485-1486.
- 144 **Nelson AJ**, Montarello NJ, Cosgrove CS, Roberts-Thomson RL, Delacroix S, Chokka RG, Montarello JK, Worthley SG. Transcatheter aortic valve implantation: a new standard of care. *Med J Aust.* 2018;209(3):136-141.
- 145 Nicholls SJ, **Nelson AJ**. Rivaroxaban with or without aspirin for the secondary prevention of cardiovascular disease: clinical implications of the COMPASS Trial. *Am J Cardiovasc Drugs.* 2019. E-pub ahead of print. PMID: 30680652
- 146 Davis CS, Piper BJ, Gertner AK, **Rotter JS**. Opioid prescribing laws are not associated with short-term declines in prescription opioid distribution. *Pain Med.* 2019. E-pub ahead of print. PMID: 31365095
- 147 **Rotter JS**, Wilson L, Greiner MA, Pollack CE, Dinan M. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer. *Breast Cancer Res Treat.* 2019;176(2):445-451.
- 148 Zahnd WE, Davis MM, **Rotter JS**, Vanderpool RC, Perry CK, Shannon J, Ko LK, Wheeler SB, Odahowski CL, Farris PE, Eberth JM. Rural-urban differences in financial burden among cancer

- survivors: an analysis of a nationally representative survey. *Support Care Cancer*. 2019. E-pub ahead of print. PMID: 30972645
- 149 Gertner AK, **Rotter JS**, Shafer PR. Association between state minimum wages and suicide rates in the US. *Am J Prev Med*. 2019;56(5):645-654.
- 150 **Rotter JS**, Spencer JC, Wheeler SB. Financial toxicity in advanced and metastatic cancer: overburdened and underprepared. *J Oncol Pract*. 2019;15(4):e300-e307.
- 151 **Rotter JS**, Spencer JC, Wheeler SB. Can cancer care cost impact quality of life outcomes for the entire household? *Psychooncology*. 2019;28(4):924-927.
- 152 Mitchell AP, **Rotter JS**, Patel E, Richardson D, Wheeler SB, Basch E, Goldstein DA. Association between reimbursement incentives and physician practice in oncology: a systematic review. *JAMA Oncol*. 2019;5(6):893-899.
- 153 Gogate A, **Rotter JS**, Trogdon JG, Meng K, Baggett CD, Reeder-Hayes KE, Wheeler SB. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer. *Breast Cancer Res Treat*. 2019;174(2):343-355.
- 154 Gertner AK, **Rotter JS**, Cruden G. Effects of the Mental Health Parity and Addiction Equity Act on specialty outpatient behavioral health spending and utilization. *J Ment Health Policy Econ*. 2018;31(3):91-103.
- 155 Witt LS, **Rotter JS**, Stearns SC, Gottesman RF, Kucharska-Newton AM, Richey Sharrett A, Wruck LM, Bressler J, Sueta CA, Chang PP. Heart failure and cognitive impairment in the Atherosclerosis Risk in Communities (ARIC) Study. *J Gen Intern Med*. 2018;33(10):1721-1728.
- 156 Spencer JC, Wheeler SB, **Rotter JS**, Holmes GM. Decomposing mortality disparities in urban and rural US counties. *Health Serv Res*. 2018;53(6):4310-4331.
- 157 **Rotter JS**. The effects of patient financial burden on cancer health outcomes. PhD dissertation. University of North Carolina at Chapel Hill. Accepted May 2019.
- 158 Januzzi JL, Mahler SA, Christenson RH, **Rymer JA**, Newby LK, Body R, Morrow DA, Jaffe AS. Recommendations for institutions transitioning to high-sensitivity troponin testing: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2019;12:1059-77.
- 159 **Rymer JA**, Kaltenbach LA, Doll JA, Messenger JC, Peterson ED, Wang TY. The safety of dual antiplatelet therapy after myocardial infarction among patients with chronic kidney disease. *J Am Heart Assoc*. 2019;8(10):e012236.
- 160 **Rymer JA**, Kaltenbach LA, Kochar A, Hess CN, Gilchrist IC, Messenger JC, Harrington RA, Jolly SS, Jacobs JD, Wojdyla DM, Krucoff MW, Rao SV. Comparison of rates of bleeding and vascular complications before, during, and after trial enrollment in the SAFE-PCI Trial for women. *Circ Cardiovasc Interv*. 2019;12:e007086.
- 161 Alenezi F, Fudim M, **Rymer JA**, Dunning A, Chiswell K, Swaminathan M, Bottiger B, Velagapudi P, Nicoara A, Kisslo J, Velazquez E, Vemulapalli S, Bloomfield GS, Samad Z. Predictors and changes in cardiac hemodynamics and geometry with transcatheter aortic valve implantation. *Am J Cardiol*. 2018;123:813-819.
- 162 Kochar A, **Rymer JA**, Samad Z; Duke Cardiovascular Education Group. Disrupting fellow education through group texting: WhatsApp in fellow education? *J Am Coll Cardiol*. 2018;72:3366-69.
- 163 **Rymer JA**, Jones WS. Femoropopliteal in-stent restenosis. *Circ Cardiovasc Interv*. 2018;11(12):e007559.
- 164 **Rymer JA**, Califf RM. The evolution of PCI registries: implementing a sustainable future for health systems and clinicians. *Eurointervention*. 2018;14(10):1076-9.

- 165 **Rymer JA**, Rao SV. Preventing acute radial artery occlusion: a battle on multiple fronts. *JACC Interventions*. 2018;11(22):2251-3.
- 166 **Rymer JA**, Chen AY, Thomas L, Stafford J, Enriquez J, Goyal A, Peterson ED, Wang TY. Advanced practice provider vs. physician-only outpatient follow-up after acute myocardial infarction. *J Am Heart Assoc*. 2018;7(17):e008481.
- 167 Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, Malenka DJ, Thourani VH, **Rymer JA**, Kosinski AS. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT Registry. *J Am Coll Cardiol*. 2018;72:2701-2711.
- 168 **Rymer JA**, Templehof MW, Clare RM, Pieper KS, Granger CB, Van de Werf F, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Lopes RD, Mahaffey KW, Newby LK. Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. *Am Heart J*. 2018;201:103-110.
- 169 **Swaminathan A**, Neely M, Frankel C, Kelly F, Petrovski S, Durham M, Goldstein D, Todd J, Palmer S. Lung transplant outcomes in pulmonary fibrosis patient with telomere-related gene variants. *Chest*. 2019. E-pub ahead of print. PMID: 30978332
- 170 **Waldron NH**, Haney JC, Suarez A, Swaminathan M. The value of echo in unexpected valve disease in a patient with ischemic cardiomyopathy: less is not always the right answer. *Journal of Cardiothoracic and Vasc Anesth*. 2018;32(1):389-392.
- 171 **Waldron NH**, Cooter M, Piccini JP, Anstrom KJ, Klinger RY, Kertai MD, Podgoreanu MV, Stafford-Smith M, Newman MF, Mathew JP. Predictive ability of perioperative atrial fibrillation risk indices. *Can J Anaesth*. 2018;65(7):786-796.
- 172 Sigurdsson MI, **Waldron NH**, Bortsov AV, Smith SB, Maixner W. Genomics of cardiovascular measures of autonomic tone. *Journal of Cardiovascular Pharmacology*. 2018;71(3):180-191.
- 173 Sigurdsson MI, Eoh EJ, Chow VW, **Waldron NH**, Cleve J, Nicoara A, Swaminathan M; Multidisciplinary Echo Research Group for Enhancing Discovery (MERGED) team. Utility of angle correction for hemodynamic measurements with Doppler echocardiography. *J Cardiothorac Vasc Anesth*. 2018;32(4):1768-1744.
- 174 **Waldron NH**, Cooter M, Haney JC, Schroder JN, Gaca JG, Lin SS, Sigurdsson MI, Fudim M, Podgoreanu MV, Stafford-Smith M, Milano CA, Piccini JP, Mathew JP. Temporary autonomic blockade with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery: a randomized clinical trial. *Heart Rhythm*. 2019;16(2):178-184.
- 175 Wischmeyer PE, McMoon MM, **Waldron NH**, Dye EJ. Successful identification of anatomical markers and placement of feeding tubes in critically ill patients via camera-assisted technology with real-time video guidance. *JPEN J Parenter Enteral Nutr*. 2019;43(1):118-125.
- 176 Sigurdsson MI, Helgadóttir S, Long TE, Helgason D, **Waldron NH**, Palsson R, Indridason OS, Gudmundsdóttir IJ, Gudbjartsson T, Sigurdsson GH. Association between preoperative opioid and benzodiazepine prescription patterns and mortality after noncardiac surgery. *JAMA Surg*. 2019:e191652. E-pub ahead of print. PMID: 31215988
- 177 Williams DGA, Molinger J, Wischmeyer PE. The malnourished surgery patient: a silent epidemic in perioperative outcomes? *Curr Opin Anaesthesiol*. 2019;32(3):405-411.
- 178 Kerneis M, Nafee T, Yee MK, Kazmi HA, Datta S, **Zeitouni M**. Most promising therapies in interventional cardiology. *Curr Cardiol Rep*. 2019;21(4):26.
- 179 Guerin M, Silvain J, Gall J, Darabi M, Berthet M, Frisdal E, Hauguel-Moreau M, **Zeitouni M**, Kerneis M, Lattuca B, Brugier D, Collet JP, Lesnik P, Montalescot G. Association of serum cholesterol efflux

capacity with mortality in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2018;72(25).

- 180 Silvain J, O'Connor SA, Yan Y, Kerneis M, Hauguel-Moreau M, **Zeitouni M**, Overtchouk P, Ankri A, Brugier D, Vicaut E, Ecollan P, Galier S, Collet JP, Montalescot G; ATOLL Investigators. Biomarkers of thrombosis in ST-segment elevation myocardial infarction: a substudy of the ATOLL trial comparing enoxaparin versus unfractionated heparin. *Am J Cardiovasc Drugs*. 2018;18(6):503-511.
- 181 **Zeitouni M**, Barthelemy O, Redheuil A, Leprince P. Heart transplantation as rescue treatment of left main stem occlusion by a recurrent aortic pseudoaneurysm. *Ann Cardiol Angeiol (Paris)*. 2018;68(1):53-55.
- 182 **Zeitouni M**, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet JP, Montalescot G, Silvain J. Do patients need lifelong  $\beta$ -blockers after an uncomplicated myocardial infarction? *Am J Cardiovasc Drugs*. 2019. E-pub ahead of print. PMID: 30828768

- 1 **Aleem S**, Bhutta ZA. Neonatology, a global perspective. *Frontiers in Neonatology*. Accepted.
- 2 **Dalgaard F**, Ruwald MH, Lindhardt TB, Nume A-K, Gislason GH, Torp-Pedersen C, Pallisgaard JL. Rate and rhythm-management in older patients with atrial fibrillation and the risk of syncope and fall-related injuries. *J American Geriatric Society*. 2019.
- 3 **Edmonston D**, Wyatt C, Al-Khatib S. Atrial fibrillation and kidney disease: stuck outside the CABANA. *Kidney International*. 2019. In press.
- 4 **Edmonston D**, Wojdyla D, Mehta R, Cai X, Lora C, Cohen D, Townsend R, He J, Go A, Kusek J, Weir M, Isakova T, Pencina M, Wolf M. Single measurements of fibroblast growth factor 23 and clinical risk prediction of adverse outcomes in chronic kidney disease. *Am J Kidney Disease*. In press.
- 5 **Greene SJ**, Felker GM, Giczewska A, Kalogeropoulos AP, Ambrosy AP, Chakraborty H, DeVore AD, Fudim M, McNulty SE, Mentz RJ, Vaduganathan M, Hernandez AF, Butler J. Spironolactone in acute heart failure patients with renal dysfunction and risk factors for diuretic resistance: from the ATHENA-HF trial. *Can J Cardiol*. 2019.
- 6 **Greene SJ**, Samsky MA, Hernandez AF. Leveraging “big data” for the design and execution of clinical trials. In: *Principles and Practice of Clinical Trials*. 2019. Springer International Publishing. Awaiting publication.
- 7 **Hung A**, Li Y, Keefe FJ, Ang DC, Slover J, Perera RA, Dumenci L, Reed SD, Riddle DL. Ninety-day and one-year healthcare utilization and costs after knee arthroplasty. *Osteoarthritis Cartilage*. Accepted May 2019.
- 8 **Hung A**, Slejko JF, Lugo A, Shaya F, Haines ST, Mullins CD. Validating a budget impact model using payer insight and claims data: a framework and case study. *J Manag Care Spec Pharm*. Accepted Mar 2019.
- 9 **Hung A**, Lugo A, Mullins CD. Modeling the budgetary impact of payer utilization management strategies: an adapted framework based on lessons learned. *J Manag Care Spec Pharm*. Accepted Mar 2019.
- 10 **Lentz TA**, Goode AP, Thigpen CA, George SZ. Value-based care for musculoskeletal pain: are physical therapists ready to deliver? *Phys Ther*.
- 11 **Marquis-Gravel G**, Rao SV. Radial/ulnar arterial access considerations: step-by-step, troubleshooting, and tips-and-tricks. In: Mehran R, Young M, editors. *ACC ISLC Handbook on Coronary Interventions*. 2018.
- 12 **Marquis-Gravel G**, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the role of aspirin for the primary prevention of cardiovascular disease. *Circulation*. 2019.
- 13 **Rymer JA**, Xiang Q, Wang A, Cohen DJ, Desai ND, Kirtane AJ, Hughes GC, Harrison JK, Kosinski AS, Vemulapalli S. Factors associated with and outcomes of aborted procedures during elective transcatheter aortic valve replacement. *J Am Coll Cardiol Interv*. Accepted.
- 14 **Rymer JA**, Patel MR, Rao SV. Quality of care in interventional cardiology. *Textbook of Interventional Cardiology*, Chapter 69. Accepted.
- 15 **Swaminathan A**, Zhu H, Tapson V, Lokhnygina Y, Poms A, Kelleher Z, Gaspard E, Kennedy K, Fee B, Fortin T, Mason N, Parikh K, McMahan T. Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. *AJRCC*. Submitted.

- 16 Wang Z, Bier E, **Swaminathan A**, Parikh K, Nouls J, He M, Mammarappallil J, Luo S, Driehuys B, Rajagopal S. Using hyperpolarized  $^{129}\text{Xe}$  MR imaging and spectroscopy to characterize gas transfer impairment across cardiopulmonary disorders. ERJ. Submitted.
- 17 **Waldron NH**, Mathew JP. Essence of pacemakers and its application after cardiopulmonary bypass. In: Cheng, Martin, and David, evidence-based practice in perioperative cardiac anesthesia and surgery. 2017. Springer International Publishing. Awaiting publication.
- 18 **Waldron NH**, Sigurdsson MI, Mathew JP. Perioperative management of valvular heart disease. In: Newman, Fleisher, and Fink, Perioperative Medicine: Managing for Outcome. 2017. Saunders Elsevier. Awaiting publication.

## ABSTRACTS PRESENTED

- 1 **Aleem S**, Tolia V, Zimmerman KO, Goldberg RN, Greenberg RG. The use of hydrocortisone in the management of persistent pulmonary hypertension of the newborn (PPHN). Presented at Pediatric Academic Societies (PAS) Annual Meeting 2019 and Southeastern Association of Neonatologists Annual Meeting 2019.
- 2 **Dalgaard F**, Ruwald MH, Lindhardt TB, Nume A-K, Gislason GH, Torp-Pedersen C, Pallisgaard JL. Antiarrhythmic drugs increase the risk of fall-related injuries and syncope in patients with atrial fibrillation – a nationwide cohort study. European Society of Cardiology. 25–29 August, 2018.
- 3 **Dalgaard F**, Pallisgaard JL, Lindhardt TB, Gislason GH, Torp-Pedersen C, Ruwald MH. Rate lowering and anti-arrhythmic drugs as monotherapy or dual therapy on the risk of pacemaker implantation in patients with atrial fibrillation. European Heart Rhythm Association. 18–20 March, 2018.
- 4 **Dalgaard F**, Pallisgaard JL, Lindhardt TB, Gislason GH, Torp-Pedersen C, Ruwald MH. Socioeconomic status influences the choice of pacemaker type in atrial fibrillation - insights from Danish Nationwide Registries. American Heart Association. 10–12 November, 2018.
- 5 **Dalgaard F**, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, Caterina RD, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE Trial. American Heart Association. 10–12 November, 2018.
- 6 **Edmonston DL**. Pulmonary hypertension subtypes in chronic kidney disease. National Kidney Foundation 14th Annual National Young Investigators' Forum. May 2019. Boston, MA.
- 7 **Edmonston D**, Wojdyla D, Rupal M, Cai X, Lora C, Cohen D, Townsend RR, He J, Go A, Kusek J, Weir M, Isakova T, Pencina M, Wolf M. Single measurements of fibroblast growth Factor 23 and clinical risk prediction of adverse outcomes in chronic kidney disease. American Society of Nephrology Kidney Week. November 2018. San Diego, CA.
- 8 **Edmonston DL**, Wu J, Matsouka R, Hernandez A, Fonarow G, DeVore A. Association between the number and type of outpatient visits in high-risk heart failure patients on readmissions and mortality. American Heart Association Strategically Focused Research Network Annual Meeting. August 2018. Salt Lake City, UT.
- 9 Huber K, **Goldstein SA**, Mojdyala DM, Lopes RD, Alexander JH, Vinereanu D, Wallintin L, Granger CB, Al-Khatib SM. Characteristics and outcomes of atrial fibrillation in patients with a diagnosis of thyroid disease: an analysis of the ARISTOTLE trial. American Heart Association Scientific Sessions. November 11, 2018, Chicago, IL.
- 10 **Goldstein SA**, D'Ottavio A, Spears T, Chiswell K, Weidemeyer M, Spates T, Krasuski RA, Kemper AR, Meyer RE, Hoffman T, Walsh MJ, Sang CJ, Paolillo J, Li JS. Causes of death in adults with congenital heart disease differ by lesion severity. American Heart Association Scientific Sessions. November 10, 2018, Chicago, IL.
- 11 **Grabert BK**, Speizer IS, Domino ME, Frerichs L, Corneli A, Fried BJ (USA). The Association of Religious Leaders' teachings and opinions about family planning in urban Senegal. 5th International Conference on Family Planning. November 12–15, 2018, Kigali, Rwanda.
- 12 Ammon S, Bozkurt B, Chung E, Cole R, Desvigne-Nickens P, Fiuzat M, **Greene SJ**, Kraus D, Ky B, McIlvennan C, Shah P, Teerlink J, O'Connor CM. Heart Failure Society of America Research Network Survey. HFSA 2018. Nashville, TN. J Card Fail. 2018;24:S9.

- 13 Samman Tahhan A, Vaduganathan M, **Greene SJ**, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O'Connor CM, Butler J. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials. HFSA 2018. Nashville, TN. J Card Fail. 2018;24:S58-59.
- 14 Patel RB, Vaduganathan M, Rikhi A, Chakraborty H, **Greene SJ**, Hernandez AF, Felker GM, Redfield M, Butler J, Shah SJ. History of atrial fibrillation and trajectory of decongestion in acute heart failure: a pooled, patient-level analysis of the Heart Failure Network. AHA 2018. Chicago, IL. Circulation. 2018;138:A10678.
- 15 Khan MS, Memon MM, Vaduganathan M, **Greene SJ**, Murad MH, Hall ME, Triposkiadis F, Butler J. Meta-analysis assessing the association between left atrial function and heart failure with preserved ejection fraction. AHA 2018. Chicago, IL. Circulation. 2018;138:A12419.
- 16 **Greene SJ**, DeVore AD, Sheng S, Butler J, Califf RM, Fonarow GC, Hernandez AF, Matsouaka R, O'Connor C, Thomas K, Clyde W Yancy, Peterson ED, Mentz RJ. Representativeness of an acute heart failure trial by race and sex: results from a joint analysis of the ASCEND-HF trial and the GWTG-HF registry. AHA 2018. Chicago, IL. Circulation. 2018;138:A12400.
- 17 **Greene SJ**, Felker GM, Giczevska A, Kalogeropoulos AP, Ambrosy AP, Chakraborty H, DeVore AD, Fudim M, McNulty ME, Mentz RJ, Vaduganathan M, Hernandez AF, Butler J. Spironolactone in acute heart failure patients with renal dysfunction and risk factors for diuretic resistance: from the ATHENA-HF trial. AHA 2018. Chicago, IL. Circulation. 2018;138:A10456.
- 18 **Greene SJ**, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Lewis EF, Maggioni AP, Böhm M, Zannad F, Butler J. Timing of randomization during hospitalization for heart failure, patient profile, and clinical trial performance: insights from the ASTRONAUT trial. AHA 2018. Chicago, IL. Circulation. 2018;138:A10479.
- 19 **Greene SJ**, Wilson L, Abbasi S, Yusuf A, Hammill BG. Outpatient use of intravenous diuretics for treatment of heart failure: temporal trends and associations with 30-day mortality and readmission following hospitalization for heart failure. AHA 2018. Chicago, IL. Circulation. 2018;138:A10391.
- 20 **Greene SJ**, Fonarow GC, DeVore A, Sharma P, Vaduganathan M, Albert N, Duffy C, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams F, Hernandez A, Butler J. Longitudinal changes in medication dosing among patients with heart failure with reduced ejection fraction: from the CHAMP-HF registry. ACC 2019. New Orleans, LA. J Am Coll Cardiol. 2019;73:707.
- 21 Rusch S, Fieldman L, **Hemmersbach-Miller M**, Wolfe CR. Opening the doors of hope: HIV-positive living kidney donation. American Transplantation Congress 2019. Accepted for oral presentation.
- 22 Blasi M, Stadler H, Chang J, **Hemmersbach-Miller M**, Gao F, Wolfe C, Klotman M. HIV+ to HIV+ kidney transplant: tracking donor and recipient virus in urine and blood. CROI 2019.
- 23 Rusch S, Fieldman L, Keicher K, Elliott S, **Hemmersbach-Miller M**, C Wolfe. Living for HOPE – building a successful living HIV+ donor transplant program. 27th Annual UNOS Transplant Management Forum TMF 2019. May 14–16, 2019. Orlando, FL.
- 24 **Hemmersbach-Miller M**, Wolfe CR. Clinical Case Challenge on Diagnostics and AMR, organized by the London School of Hygiene and Tropical Medicine's International Diagnostics Centre [made top 3 finalists], 2018. Case #18016: A man returning from India with a new liver and an infectious souvenir. [Internet]. Partners Infectious Disease Images. Available from: <http://www.idimages.org/idreview/case/caseid=558>. Invited speaker at the Clinical Diagnostics and Antimicrobial Resistance: A Multidisciplinary Symposium organized by the LSHTM, November 1, 2018. London, UK.

- 25 Messina JA, **Hemmersbach-Miller M**, Alexander BD, Chao NJ, Sung AD. Impact of enterococcal bloodstream infection on mortality in patients with acute leukemia receiving intensive chemotherapy. ID Week 2018. October 5, 2018, San Francisco, CA.
- 26 **Hemmersbach-Miller M**, Wolfe CR. Giving the gift of life – HIV-positive living organ donation. Annual Duke Center for AIDS Research (CFAR) Fall Scientific Retreat. September 27, 2018, Durham, NC.
- 27 **Hung A**, Li Yanhong, Keefe FJ, Ang DC, Slover J, Jensen MP, Bair MJ, Kroenke K, Perera RA, McKee D, Dumenci L, Reed SD, Riddle DL. One-year healthcare utilization and costs after knee arthroplasty [poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. May 2019, New Orleans, LA.
- 28 **Inohara T**, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. ACC 2018. Orlando, FL.
- 29 **Inohara T**, Vemulappali S, Kohsaka S, Watanabe Y, Shirai S, Tada N, Arai M, Naganuma T, Ymanaka F, Ueno H, Tabata M, Higashimori A, Takagi K, Yamamoto M, Hayashida K. Appropriateness of transcatheter aortic valve replacement, insight from the OCEAN TAVI Registry. TCT 2018. San Diego, CA.
- 30 **Inohara T**, Shrader P, Pieper K, Blanco RG, Fonarow GC, Gersh BJ, Go AS, Kowey RP, Mahaffey KW, Peterson ED, Piccini JP. Treatment patterns and clinical outcomes in adults with concomitant atrial fibrillation and vascular disease. AHA (American Heart Association Scientific Sessions) 2018. Chicago, IL.
- 31 **Inohara T**, Liang L, Kosinski A, Smith EE, Schwamm LH, Hernandez AF, Bhatt DL, Fonarow GC, Peterson ED, Xian Y. Intravenous recombinant tissue plasminogen activator in acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. AHA (American Heart Association Scientific Sessions) 2018. Chicago, IL.
- 32 **Inohara T**, Ichihara N, Kohsaka S, Miyata H, Hirata Y, Murakami A, Shimizu H, Aeba R. The effect of body weight in infants undergoing ventricular septal defect closure: a report from the Nationwide Japanese Congenital Surgical Database. AHA (American Heart Association Scientific Sessions) 2018. Chicago, IL.
- 33 **Inohara T**, Liang L, Kosinski A, Smith EE, Schwamm LH, Hernandez AF, Bhatt DL, Fonarow GC, Peterson ED, Xian Y. Intravenous recombinant tissue plasminogen activator in acute ischemic stroke patients with recent myocardial infarction. ISC (International Stroke Conference) 2019. Hawaii.
- 34 **Jawitz OK**, Raman V, Barac Y, Mulvihill M, Moore C, Choi A, Hartwig M, Klapper J. Time from lung transplant donor brain death to cross clamp: an analysis of the UNOS Registry. Oral presentation at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 35 **Jawitz OK**, Raman V, DeVore AD, Mentz RJ, Patel CB, Rogers J, Hartwig M, Daneshmand M, Milano C. Increasing the US heart transplant donor pool by greater than 30%: the potential of donation after circulatory death donors. Oral presentation at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 36 **Jawitz OK**, Aman M, Turner M, Gilmore B, Migaly J. Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. Oral presentation at the Academic Surgical Congress. February 2019, Houston, TX.

- 37 Raman V, Yang CF, **Jawitz OK**, et al. The role of adjuvant therapy for patients with early stage large cell neuroendocrine lung cancer: a national analysis. Presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer. September 2018, Toronto, Canada.
- 38 **Jawitz OK**, Cox ML, Ranney D, Williams JB, Mulder H, Gaudino MFL, Fremes S, Habib R, Gibson CM, Schwann TA, Lopes RD, Alexander JH. Angiographic and clinical outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. Oral presentation at the American Association for Thoracic Surgery Annual Meeting. May 2019, Toronto, Canada.
- 39 Choi AY, **Jawitz OK**, Raman V, Barac Y, Mulvihill MS, Moore C, Hartwig MG. Unfavorable characteristics of donation after circulatory death donors: an analysis of UNOS. Presented at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 40 Barac Y, **Jawitz OK**, Daneshmand M, Schroder J, Patel C, Milano C. LVAD patients with RV failure pre-heart transplant have reduced post-transplant survival. Presented at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 41 Barac Y, **Jawitz OK**, Raman V, Klapper J, Schroder J, Patel C, Daneshmand M, Hartwig M, Milano C. Mitigating the impact of gender mismatch in heart transplantation using BMI and BSA ratios. Presented at the International Society for Heart and Lung Transplantation Annual Meeting April 2019. Orlando, FL.
- 42 Barac Y, **Jawitz OK**, Klapper J, Schroder J, Daneshmand M, Patel C, Hartwig M, Milano C. Heart transplantation survival and the use of traumatically brain injured donors. Presented at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 43 Barac Y, Mulvihill M, **Jawitz OK**, Daneshmand M, Klapper J, Hartwig M, Haney J. High calculated panel reactive antigen (cPRA) is associated with decreased rates of transplantation and increased waitlist mortality in lung transplantation: a UNOS/OPTN registry analysis. Presented at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 44 Barac Y, Klapper J, Poisson J, Zaffiri L, Pollak A, Seay T, **Jawitz OK**, Haney J, Daneshmand M, Welsby I, Hartwig M, Bottiger B. Anticoagulation strategies in the perioperative period for lung transplant: 4-factor prothrombin complex concentrate for warfarin reversal. Presented at the International Society for Heart and Lung Transplantation Annual Meeting. April 2019, Orlando, FL.
- 45 Slaughter MS, Badhwar V, Ising M, Ganzel BL, Sell-Dottin K, **Jawitz OK**, Zhang S, Trivedi J. Optimum surgical treatment for tricuspid valve infective endocarditis: analysis of STS national database. Presented at the American Association for Thoracic Surgery Annual Meeting. May 2019, Toronto, Canada.
- 46 Rodriguez-Homs L, Masoud S, **Jawitz OK**, Phillips H, O'Brien C, Mosca PJ. Improved compliance with early sepsis management is associated with shorter hospital stay. Presented at the Institute for Healthcare Improvement 2018 National Forum. December 2018, Orlando, FL.
- 47 Masoud S, Rodriguez-Homs L, **Jawitz OK**, Phillips H, Mosca PJ. Patient ratings of discharge information and care transition in HCAHPS survey predict 30-day CABG mortality and readmission rates. Presented at the Institute for Healthcare Improvement 2018 National Forum. December 2018, Orlando, FL.
- 48 Gbadegesin RA, Davis TK, Wenderfer SE, Gibson KL, Selewski DT, Barcia JT, Weng PL, Licht C, Foreman JW, Wigfall DR, Chua AN, Pelletier JH, Tsai EW, Hornik CP, Nagaraj SK, Greenbaum LA, **Kumar KR**, Engen RM, Bensimhon AR, Varner JD, Rheault M, Srivastava T, D'Alessandri-Silva CJ. Risk stratification for disease recurrence in children with steroid resistant nephrotic syndrome (SRNS) following kidney transplantation (Midwest Pediatric Nephrology Consortium [MWPNC] study). American Society of Nephrology Kidney Week. 2018, San Diego, CA.
- 49 Ciociola EC, **Kumar KR**, Sullivan LN, Thompson EJ, Harward M, Zimmerman KO, Turek JW, Hornik CP. Association between preoperative support and outcomes in pediatric cardiac surgery. Pediatric Academic Societies Meeting. 2019, Baltimore, MD.

- 50 **Lentz TA**, Rhon DI, George SZ. Do pain intensity and disability directly influence healthcare utilization and costs for musculoskeletal pain? Poster presented at International Association for the Study of Pain (IASP) 17th World Congress. Boston, MA.
- 51 **Lentz TA**, Zeppieri G, Bialosky JE, George SZ. Patient-centered outcomes: domain importance predicts health care utilization following physical therapy. Platform presented at APTA Combined Sections Meeting. Washington, DC.
- 52 **Lentz TA**, O'Donnell JD, Ross MA, Jiranek WA, Mather RC III. Patient subgrouping to inform treatment pathway development for a comprehensive osteoarthritis care program. Platform presented at APTA Combined Sections Meeting. Washington, DC.
- 53 Ross MA, O'Donnell JD, **Lentz TA**, Mather RC III, Jiranek WA. Development and implementation of a comprehensive lifestyle and behavioral health management program for osteoarthritis: a new role for physical therapists. Platform presented at APTA Combined Sections Meeting. Washington, DC.
- 54 **Lentz TA**, O'Donnell JD, Malay MA, Jiranek WA, Mather RC III. Patient subgrouping to inform treatment pathway development for a comprehensive osteoarthritis care program. Poster presented at American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting. Las Vegas, NV.
- 55 O'Donnell JD, Malay MA, **Lentz TA**, Jiranek WA, Mather RC III. Early results of a longitudinal, comprehensive lifestyle and behavioral health modification program for osteoarthritis. Poster presented at American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting. Las Vegas, NV.
- 56 **Lentz TA**, Magill J, Myers H, Esposito V, Messer M, Reinke E, Riboh JC. Development of a concise lower extremity physical performance test set for return to sport decision-making in pediatric populations. Poster presented at Pediatric Research in Sports Medicine (PRiSM) Annual Meeting. Atlanta, GA.
- 57 **Lentz TA**, Simon CB, King HA, Allen KD, George SZ, Hastings SN. Challenges to implementing guideline concordant care for low back pain: update from a pragmatic trial in the Veteran's Health Administration System. Platform presented at Center on Health Services Training and Research (CoHSTAR) Summer Institute. Providence, RI.
- 58 Zeitler EP, Friedman DJ, **Loring Z**, Campbell KB, Goldstein SA, Wegermann ZK, Schultz J, Smith N, Black-Maier E, Al-Khatib SM, Piccini JP. Common and uncommon complications involving the S-ICD: lessons learned from MAUDE. Heart Rhythm Society Scientific Sessions. May 2019, San Francisco, CA.
- 59 Black-Maier E, Parish A, Steinberg B, Green C, **Loring Z**, Barnett A, Al-Khatib S, Atwater BD, Daubert JP, Frazier-Mills C, Hegland DD, Jackson K, Jackson L, Koontz J, Pokorney S, Sun AY, Thomas K, Bahnon B, Piccini JP. Predicting recurrence of atrial fibrillation after catheter ablation in patients with heart failure: validity of the APPLE and CAAP-AF risk scoring systems. Heart Rhythm Scientific Sessions. May 2019, San Francisco, CA.
- 60 **Loring Z**, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Peterson ED, Piccini JP. Association between guideline-directed medical therapies for comorbid conditions and clinical outcomes among individuals. American College of Cardiology. 2019.
- 61 **Lowenstern A**, Navar AM, Li S, Virani SS, Koren A, Louie MJ, Robinson JG, Roger VL, Goldberg AC, Peterson ED, Wang TY. Patient perceptions and management of cholesterol among individuals with or without patient perceptions and in community practice: Results from the PALM Registry. Presented as a moderated poster at American College of Cardiology Scientific Sessions. March 16–18, 2019.
- 62 **Lowenstern A**, Sheridan P, Boero I, Wang TY, Vemulapalli S, Thourani VH, Leon MB, Peterson ED, Brennan JM. Race and sex-based disparities persist in the treatment of patients with severe, symptomatic aortic valve stenosis. Presented at American College of Cardiology Scientific Sessions. March 16–18, 2019.

- 63 Rymer J, Kennedy K, **Lowenstern A**, Secemsky E, Aronow H, Gray B, Prasad A, Armstrong E, Rosenfield K, Shisheor M, Jones S, Patel M. In-hospital outcomes and discharge medication use among patients presenting with critical limb ischemia versus claudication: insights from the NCDR PVI Registry. American College of Cardiology Scientific Sessions. March 16–18, 2019.
- 64 **Lowenstern A**, Lipmann SJ, Brennan JM, Wang TY, Curtis L, Feldman T, Glower DD, Hammill BG, Vemulapalli S. Use of medicare data to identify structural heart disease outcomes in mitral regurgitation. Presented as an oral presentation at American Heart Association Scientific Sessions and Resuscitation Science Symposium. November 10–12, 2018.
- 65 Cooper LB, Zeitler EP, Clare R, Chiswell K, **Lowenstern A**, Rogers JG, Milano CA, Schroder JN, Al-Khatib S, Mentz RJ. What is the role of OptiVol for volume assessment in patients with a continuous flow LVAD? Presented at American Heart Association Scientific Sessions and Resuscitation Science Symposium. November 10–12, 2018.
- 66 **Marquis-Gravel G**, Stebbins A, Kosinski A, Cox M, Harrison JK, Hughes JC, Thourani V, Vemulapalli S. Does driving time to the transcatheter aortic valve replacement site impact on long-term mortality following a successful procedure? Insights from the STS/ACC TVT Registry. *Circulation: Cardiovascular Quality and Outcomes*. 2019;12(Suppl 1):A250.
- 67 **Marquis-Gravel G**, Neely M, Valgimigli M, Costa F, Klaveren DV, Bhatt DL, Altner R, Armstrong PW, Fox KA, White HD, Ohman EM, Roe M. Comparison of the performance of long-term bleeding risk prediction models with dual antiplatelet therapy in patients with acute coronary syndromes treated without revascularization. *JACC*. 2019;73(9 Suppl 1):66.
- 68 **Mosher C**, Rackley C. Searching for a buzz: glitter lava lamp will take your breath away. Poster presentation, CHEST Annual Meeting. October 2018, San Antonio, TX.
- 69 Turner D, **Mosher C**, Patel S, Pumill C, Sillings C, Sporn T, Barkauskas C. Saved by silver stain: a case of disseminated histoplasmosis. Poster presentation, CHEST Annual Meeting. October 2018, San Antonio, TX.
- 70 **Nanna MG**, Navar AM, Wojdyla D, Peterson ED. The impact of hyperlipidemia on cardiovascular risk in older adults age  $\geq 75$ : results from the NHLBI Pooled Cohorts. *J Am Coll Cardiol*. 2019 Mar;73(9 Supplement 1):1693. DOI: 10.1016/S0735-1097(19)32299-5. Presented at the American College of Cardiology, Scientific Sessions 2019. March 2019, New Orleans, LA.
- 71 **Nanna MG**, Navar AM, Wang TY, Li S, Li Z, Robinson JG, Roger VL, Virani SS, Wilson PWF, Goldberg AC, Koren A, Louie MJ, Peterson ED. Practice-level variation in statin use and LDL-control in the United States: results from the Patient and Provider Assessment of Lipid Management (PALM) Registry. *J Am Coll Cardiol*. 2019 Mar;73(9 Supplement 1):1706. DOI: 10.1016/S0735-1097(19)32312-5. Presented at the American College of Cardiology, Scientific Sessions 2019. March 2019, New Orleans, LA
- 72 Dodson JA, Hajduk A, Geda M, Krumholz HM, Murphy T, Tsang S, Tinetti M, **Nanna MG**, McNamara R, Gill T, Chaudhry S. Mortality prediction for older adults with AMI: the SILVER-AMI Study. *J Am Coll Cardiol*. 2019 Mar;73(9 Supplement 1):102. DOI: 10.1016/S0735-1097(19)30710-7. Presented at the American College of Cardiology, Scientific Sessions 2019. March 2019, New Orleans, LA.
- 73 **Nanna MG**, Peterson ED, Wojdyla D, Navar AM. Do the pooled cohort equations accurately predict cardiovascular disease risk in older adults? *Circulation*. 2019 Mar;139:AP010; DOI: [https://doi.org/10.1161/circ.139.suppl\\_1.P010](https://doi.org/10.1161/circ.139.suppl_1.P010). Presented at the American Heart Association, EPI|Lifestyle Scientific Sessions 2019. March 2019, Houston, TX.
- 74 **Nanna MG**, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, Peterson ED, Navar AM. Sex differences in the use of statins in community practice: the

- PALM Registry. Presented at the American Heart Association, Scientific Sessions 2018, National Meeting. November 2018, Chicago, IL.
- 75 **Nanna MG.** Zebra hunting in Durham, North Carolina: a tick-borne cause of fulminant myocarditis? Presented at the Nightmare Cases in the Cath Lab session at the 27th Annual Cardiovascular Conference. February 2019, Beaver Creek, CO.
- 76 Sullivan AE, **Nanna MG**, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Yee MK, Kong DF. A systematic review of randomized and non-randomized studies comparing dual therapy with triple therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2018. September 2018, San Diego, CA.
- 77 **Rymer JA**, Kennedy K, Lowenstern AM, Secemsky E, Tsai TC, Aronow HD, Prasad A, Gray B, Armstrong E, Rosenfeld KI, Shishehbor M, Jones WS, Patel MR. In-hospital outcomes and discharge medication use among patients presenting with critical limb ischemia vs. claudication: insights from the NCDR PVI Registry. Oral Presentation at American College of Cardiology 2019. New Orleans, LA.
- 78 **Rymer JA.** High sensitivity troponin in low risk chest pain: the cardiologist's friend or foe? Invited oral presentation at American College of Cardiology 2019. New Orleans, LA.
- 79 **Rymer JA.** The mechanics of a high sensitivity troponin rollout: pearls and pitfalls. Invited oral presentation at American College of Cardiology 2019. New Orleans, LA.
- 80 **Rymer JA**, Xiang K, Vemulapalli S. Predictors and outcomes of aborted procedures during elective transcatheter aortic valve replacement. Oral presentation at TCT 2019. San Diego, CA.
- 81 **Rymer JA**, Li S, Wang TY. Patient perceptions of care and outcomes in the post-myocardial infarction population. Poster presented at American Heart Association 2018 Meeting. Chicago, IL.
- 82 **Rymer JA**, Kaltenbach LA, Doll JA, Messenger JC, Peterson ED, Wang TY. The safety of dual antiplatelet therapy after myocardial infarction among patients with chronic kidney disease. Poster presented at American Heart Association 2018 Meeting. Chicago, IL.
- 83 **Swaminathan A**, O'Brien E, Hellkamp A, Neely M, Bender S, Snyder L, Culver D, Conoscenti C, Todd J, Palmer S, Leonard T. Health-related quality of life measures in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. *Chest*. 2019. New Orleans, LA.
- 84 Bier E, Wang Z, **Swaminathan A**, Nouls J, He M, Mammarrappallil J, Luo S, Driehuys B, Rajagopal S. 129 Xenon MR imaging and spectroscopic signatures differentiate pulmonary arterial hypertension from other heart and lung disease. American Thoracic Society International Conference. 2019, Dallas, TX.
- 85 **Swaminathan A**, Neely ML, Frankel CW, Kelly FL, Petrovski S, Durham MT, Goldstein DB, Palmer SM, Todd JL. Lung transplant outcomes in pulmonary fibrosis patients with telomere-related gene mutations. American Thoracic Society International Conference. 2018, San Diego, CA.
- 86 **Swaminathan A**, Bier E, Nouls J, Kennedy K, Almeida-Peters S, Womack S, Driehuys B, Rajagopal S. Non-invasive diagnosis of pulmonary vascular disease with inhaled 129 Xenon MRI. American Heart Association Scientific Sessions. 2018, Chicago, IL.
- 87 **Swaminathan A**, Lokhnygina Y, Zhu H, Kennedy K, Mason SN, Kelleher Z, Fee B, Poms A, Tapson V, McMahon T. Asymmetric dimethylarginine and symmetric dimethylarginine as novel biomarkers in patients with pulmonary (arterial) hypertension. *American Journal of Respiratory and Critical Care Medicine*. 2018;197:A2127.
- 88 Kamath A, Cooper A, Willis M, Hale S, Lovins J, **Swaminathan A**, Wachter A. Inter-professional quality improvement project to improve the safety of discharge medication reconciliation process for hospitalized patients. *Hospital Medicine*. 2018, Orlando, FL.

- 89 **Waldron NH**, Flynn A, Browndyke JN, Kertai MD, Podgoreanu MV, Newman MF, Song AW, Mathew JP. Brain functional network connectivity and postoperative atrial fibrillation: is it all in our heads? Best of Meetings Session, 2017 Society for Cardiovascular Anesthesiologists Meeting.
- 90 **Waldron NH**, Cooter M, Quinones QJ, Klinger RY, Kertai MD, Piccini JP, Mathew JP. Preventing postoperative atrial fibrillation with beta-blockade: is timing important? 2017 Society for Cardiovascular Anesthesiologists Meeting.
- 91 **Waldron NH**, Cooter M, Haney JC, Schroder JN, Milano CA, Piccini JP, Mathew JP. Temporary neurotoxin treatment to prevent postoperative atrial fibrillation (TNT-POAF). Late-Breaking Clinical Trials Session, 2017 American Heart Association Meeting.
- 92 **Waldron NH**. Postoperative atrial fibrillation. 2019 Society of Cardiovascular Anesthesiologists (SCA) Meeting. May 2019, Chicago, IL.
- 93 **Waldron NH**. Autonomic modulation for postoperative atrial fibrillation. Invited lecture—Massachusetts General Anesthesiology Research Meeting. June 2019.
- 94 **Zeitouni M**, Collet JP, Hulot JS, Silvain J, Kerneis M, Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve JB, Payot L, Brugier D, Galier S, Diallo A, Vicaut E, Montalescot G. P4207. The natural history of premature coronary artery disease over 20 years: the AFIJI registry. *Eur Heart J*. [Internet] 2018. [cited 2019 Feb 14]
- 95 **Zeitouni M**, Collet JP, Silvain J, Hulot JS, Kerneis M, Lavie-Badie Y, Barthelemy O, Payot L, Esteve JB, Lattuca B, Galier S, Brugier D, Diallo A, Vicaut E, Montalescot G. Professional status and long-term prognosis of premature coronary artery disease: the AFIJI registry. *Eur Heart J*. 2018.
- 96 Collet JP, **Zeitouni M**, Hulot JS, Silvain J, Barthelemy O, Kerneis M, Lattuca B, Lavie-Badie Y, Payot L, Esteve JB, Brugier D, Galier S, Diallo A, Vicaut E, Montalescot G. P6233. Intima-media thickness to better risk-stratify patients with premature coronary artery disease: an analysis from the AFUI registry. *Eur Heart J*. 2018.